U.S. patent application number 11/902183 was filed with the patent office on 2008-07-24 for compounds that interact with kinases.
This patent application is currently assigned to ALCHEMIA LIMITED. Invention is credited to Natalie Bouloc, Fiona Foley, Wim Meutermans, Craig Muldoon, Karl Schafer, Gerald Tometzki, Michael L. West.
Application Number | 20080176815 11/902183 |
Document ID | / |
Family ID | 27671568 |
Filed Date | 2008-07-24 |
United States Patent
Application |
20080176815 |
Kind Code |
A1 |
Meutermans; Wim ; et
al. |
July 24, 2008 |
Compounds that interact with kinases
Abstract
A method of inhibiting or effecting the activity of protein
kinase activity which comprises contacting a protein kinase with a
compound of formula (I) being a derivative of a furanose or
pyranose form of a monosaccharide, or a pharmaceutically acceptable
salt thereof.
Inventors: |
Meutermans; Wim; (Toowong,
AU) ; Schafer; Karl; (Carindale, AU) ; West;
Michael L.; (Hemmant, AU) ; Muldoon; Craig;
(Coburg, AU) ; Foley; Fiona; (Greenslopes, AU)
; Bouloc; Natalie; (Carshalton, GB) ; Tometzki;
Gerald; (Manly West, AU) |
Correspondence
Address: |
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON
VA
22203
US
|
Assignee: |
ALCHEMIA LIMITED
Eight Mile Plains
AU
|
Family ID: |
27671568 |
Appl. No.: |
11/902183 |
Filed: |
September 19, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10526388 |
Jun 2, 2005 |
7291623 |
|
|
PCT/AU03/01146 |
Sep 5, 2003 |
|
|
|
11902183 |
|
|
|
|
Current U.S.
Class: |
514/45 ; 514/385;
514/394; 514/397; 514/43 |
Current CPC
Class: |
A61P 43/00 20180101;
A61K 31/7076 20130101; A61K 31/7056 20130101; A61K 31/708 20130101;
A61P 17/06 20180101; A61P 29/00 20180101; C07H 17/08 20130101; A61P
35/02 20180101; A61P 9/10 20180101; A61P 31/12 20180101; A61P 9/00
20180101; A61P 33/14 20180101; C07H 17/02 20130101; A61P 35/00
20180101 |
Class at
Publication: |
514/45 ; 514/385;
514/397; 514/394; 514/43 |
International
Class: |
A61K 31/7056 20060101
A61K031/7056; A61K 31/4178 20060101 A61K031/4178; A61K 31/4184
20060101 A61K031/4184; A61P 29/00 20060101 A61P029/00; A61P 9/00
20060101 A61P009/00; A61P 35/00 20060101 A61P035/00; A61K 31/7076
20060101 A61K031/7076 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 6, 2002 |
AU |
2002951247 |
Claims
1-66. (canceled)
67. A method of inhibiting or effecting protein kinase activity
which comprises contacting a protein kinase with a compound of
formula I being a derivative of a furanose or pyranose form of a
monosaccharide, or a pharmaceutically acceptable salt thereof
##STR00282## Wherein; n is 1 or 2, X is selected from the group
consisting of: OR1, an unsubstituted 5 or 6 membered heterocyclic
moiety, a substituted 5 or 6 membered heterocyclic moiety, an
unsubstituted 9 or 10 membered heterobicyclic moiety and a
substituted 9 or 10 membered heterobicyclic moiety, R1 is selected
from the group consisting of: C1 to C7 alkyl, C1 to C7 alkenyl, C1
to C7 alkynyl, C1 to C7 heteroalkyl, C.sub.6 to C.sub.14 aryl,
C.sub.3 to C.sub.14 heteroaryl, C.sub.6 to C.sub.14 arylalkyl and
C.sub.3 to C.sub.14 heteroarylalkyl, Y is selected from the group
consisting of an unsubstituted 5 or 6 membered heterocyclic moiety;
a substituted 5 or 6 membered heterocyclic moiety, an unsubstituted
9 or 10 membered heterobicyclic moiety and a substituted 9 or 10
membered heterobicyclic moiety; an amino acid, a dipeptide, and
##STR00283## R6 is selected from the group consisting of: H, C1 to
C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7 heteroalkyl,
C6 to C14 aryl, C3 to C14 heteroaryl, C6 to C14 arylalkyl or C3 to
C14 heteroarylalkyl, with the proviso that R6, R7 and R8 are not
all H, R9 is selected from H, or --(CO)--R6, R7, R8, R11, R12, R14,
are independently selected from the group consisting of: H, C1 to
C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7 acyl, C1 to
C7 heteroalkyl, C6 to C14 aryl, C6 to C14 arylacyl, C6 to C14
heteroaryl, C6 to C14 heteroarylacyl, C6 to C14 arylalkyl and C6 to
C14 heteroarylalkyl, R13 is selected from the group consisting of:
unsubstituted phenyl unsubstituted benzyl, substituted phenyl,
substituted benzyl, H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7
alkynyl, C1 to C7 acyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C6 to
C14 arylacyl, C6 to C14 heteroaryl, C6 to C14 heteroarylacyl, C6 to
C14 arylalkyl or C6 to C14 heteroarylalkyl, --S--R6 and --O--R6,
R15 is absent or is at least one substituent on the aromatic ring
which are independently selected from the group consisting of: OH,
NO, NO.sub.2, NH.sub.2, N.sub.3, halogen, CF.sub.3, CHF.sub.2,
CH.sub.2F, nitrile, alkoxy, aryloxy, amidine, guanidiniums,
carboxylic acid, carboxylic acid ester, carboxylic acid amide,
aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl,
aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or
unsubstituted imine, sulfate, sulfonamide, phosphate,
phosphoramide, hydrazide, hydroxamate, hydroxamic acid,
heteroaryloxy, alkyl, aminoaryl, aminoheteroaryl, thioalkyl,
thioaryl and thioheteroaryl.
68. The method of claim 67, wherein R1 is substituted, cyclic or
acyclic, branched and/or linear.
69. The method of claim 67, wherein R7 and R8 combine to form a
cyclic structure.
70. The method of claim 67, wherein R6 and one of R7 or R8 combine
to form a cyclic structure.
71. The method of claim 67, wherein R11 and R12 combine to form a
cyclic structure,
72. The method of claim 67, wherein X is selected from: OR1,
##STR00284## R1 and R3 are independently selected from the group
consisting of: C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl,
C1 to C7 heteroalkyl, C6 to C14 aryl, C3 to C14 heteroaryl, C6 to
C14 arylalkyl and C3 to C14 heteroarylalkyl, R4 is selected from
the group consisting of: H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to
C7 alkynyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C3 to C14
heteroaryl, C6 to C14 arylalkyl and C3 to C14 heteroarylalkyl, R5
is selected from the group consisting of: H, C1 to C7 alkyl, C1 to
C7 alkenyl, C1 to C7 alkynyl, C1 to C7 heteroalkyl, C6 to C14 aryl,
C3 to C14 heteroaryl, C6 to C14 arylalkyl or C3 to C14
heteroarylalkyl, C1 to C7 acyl, C6 to C14 arylacyl, and C3 to C14
heteroarylacyl, R2 is selected from the group consisting of:
--(C.dbd.O)--R3, --(C.dbd.O)--OR4, and --(C.dbd.O)--NH--R4, Y is
selected from: ##STR00285##
73. The method of claim 72, wherein at least one of R1 to R5 is
substituted, cyclic or acyclic, branched and/or linear.
74. The method of claim 72, wherein R7 and R8 combine to form a
cyclic structure.
75. The method of claim 72, wherein R6 and one of R7 or R8 combine
to form a cyclic structure.
76. The method of claim 72, wherein R11 and R12 combine to form a
cyclic structure.
77. The method of claim 67 wherein at least one of R1-R14 is
substituted and these substituents and the substituents on the
substituted 5 or 6 membered heterocyclic moiety and the substituted
9 or 10 membered heterobicyclic moiety are selected from the group
consisting of: OH, NO, NO.sub.2, NH.sub.2, N.sub.3, halogen,
CF.sub.3, CHF.sub.2, CH.sub.2F, nitrile, alkoxy, aryloxy, amidine,
guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic
acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl,
aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or
unsubstituted imine, sulfate, sulfonamide, phosphate,
phosphoramide, hydrazide, hydroxamate, hydroxamic acid,
heteroaryloxy, alkyl, aminoaryl, aminoheteroaryl, thioalkyl,
thioaryl or thioheteroaryl, which may optionally be further
substituted.
78. The method of claim 67 wherein the group X is ##STR00286##
79. The method of claim 67, wherein the group X is ##STR00287##
80. The method of claim 67, wherein X is --OR1
81. The method of claim 72 wherein the group Y is ##STR00288##
82. The method of claim 72 wherein Y is ##STR00289##
83. The method of claim 72, wherein Y is ##STR00290##
84. The method of claim 72, wherein Y is ##STR00291##
85. The method of claim 72, wherein Y is ##STR00292##
86. The method of claim 72, wherein Y is ##STR00293##
87. The method of claim 72, wherein Y is ##STR00294##
88. The method of claim 67 wherein the protein kinase is a serine
or threonine kinase.
89. The method of claim 67 wherein the protein kinase is a tyrosine
kinase.
90. The method of claim 67 wherein the protein kinase is selected
from the group consisting of one or more of the isoforms of: A
protein kinase C; B Tie-2, also known as TEK, HPK-6, TIE-2, VMCM,
VMCM1; C c-Kit, also known as SCFR, CD117, PBT; D VEGF-R2/KDR; also
known as VEGFR2, VEGFR-2, VEGFR, Hs.KDR, Hs.12337, FLK1, FLK-1; E
EGF-R, also known as ERBB1, ERBB, EGFRvIII; F Abl, also known as
c-ab1, c-ABL, JTK7, p150, ABL1; G MET, also known as HGFR, C-MET,
RCCP2; H CDK2, also known as p34CDK2, p33CDK2, p33CDK2; I PDGF,
also known as PDGFR1, PDGFR, PDGF-R-beta, JTK12, CD140B, PDGFRB; J
FGFR-1, also known as N-SAM, LOC51033, FLT2, FLJ14326, CEK, C-FGR,
BFGFR, H5, H4, H3, H2, FLG; and K P38 MAP Kinase, also known as
p38alpha, p38ALPHA, SAPK2a, SAPK2A, PRKM15, PRKM14, Mxi2, MXI2,
Exip, EXIP, CSPB1, CSBP2, CSBP1, p38, RK, P38, MAPK14.
Description
FIELD OF THE INVENTION
[0001] The invention is directed to classes of biologically active
compounds that interact in a pharmaceutically significant manner
with protein kinases, and particularly to provide compounds
suitable for the treatment of disorders mediated by protein kinase
activity. The invention is also directed to treatment of the above
mentioned disorders. The invention is also directed to the
preparation of novel compounds per se.
BACKGROUND OF THE INVENTION
[0002] The drug discovery landscape has been transformed by the
genomics revolution. Advances in the understanding of biomolecular
pathways and the roles they play in disease is generating vast
numbers of targets for therapeutic intervention. Protein kinases
now represent an extensive and important class of therapeutic
targets.
[0003] Kinases are key components in almost all signal transduction
pathways, modulating extracellular and intracellular signalling
processes that mediate events such as cell growth and
differentiation, metabolism and apoptosis. Kinases do this by
catalysing the transfer of a phosphate group from ATP to protein
substrates. The pivotal role of kinases is emphasized by the fact
that kinases represent the third most populous domain in the
proteome.
[0004] Kinases have been implicated in many diseases. Twenty
percent of oncogenes code for tyrosine kinases. Kinases play
pivotal roles in many leukemias, tumours and other proliferative
disorders. Other states involving kinases include inflammatory
disorders such as psoriasis, cardiovascular diseases such as
restenosis, viral induced diseases such as Kaposi's sarcoma,
circulatory diseases such as atherosclerosis and fibroproliferative
diseases. Specific kinases are often implicated in particular
disease states and therefore present themselves as potential
targets for therapeutic intervention.
[0005] The kinase family includes serine/threonine kinases and
tyrosine kinases, with the amino acid referring to the particular
residue on a protein substrate that is phosphorylated. The tyrosine
kinases can be further divided into receptor tyrosine kinases and
non-receptor tyrosine kinases.
[0006] Considering the rate of generation and nature of the targets
currently being deconvoluted by biologists, there is a need for the
development of drug candidates, designed in a rational manner to
purposely interact with selected targets, such as the kinases.
[0007] From a drug discovery perspective, carbohydrate pyranose and
furanose rings and their derivatives are well suited as templates.
Each sugar represents a three-dimensional scaffold to which a
variety of substituents can be attached, usually via a scaffold
hydroxyl group, although occasionally a scaffold carboxyl or amino
group may be present for substitution. By varying the substituents,
their relative position on the sugar scaffold, and the type of
sugar to which the substituents are coupled, numerous highly
diverse structures are obtainable. An important feature to note
with carbohydrates, is that molecular diversity is achieved not
only in the type of substituents, but also in the three dimensional
presentation. The different stereoisomers of carbohydrates that
occur naturally, offer the inherent structural advantage of
providing alternative presentation of substituents. We have
developed a system that allows the chemical synthesis of highly
structurally and functionally diverse derivatised carbohydrate and
tetrahydropyran structures, of both natural and unnatural origin.
The diversity accessible is particularly augmented by the
juxtaposition of both structural and functional aspects of the
molecules.
[0008] A number of kinase inhibitors have appeared in the
scientific literature to date. Many have entered human clinical
trials and in two cases, Gleevac and Iressa, approval for the
treatment of various tumours has been granted (Cohen, P., Nature
Tev. Drug Discovery, 1, 309-316, 2002). The specificity of
published kinase inhibitors varies widely and it is apparent from
the study of Gleevac that specificity for a single kinase is not a
prerequisite for the inhibitor becoming a useful drug, indeed the
inhibition of more than one kinase may be an advantage for
therapeutic intervention. Despite some promiscuity in the target
kinase being acceptable, it is generally considered desirable to
have good selectivity for the target kinase(s) over more general
"housekeeping" kinases. Thus selectivity and inhibitor potency must
be assessed on a case by case basis.
[0009] The level of inhibition in cell based assays also shows
considerable variation from approximately 0.1 micromolar to over
100 micromolar as exemplified by the following table (a more
detailed study can be found in: Davies et. al., Biochem. J., 351,
95-105, 2000; and Bain et. al., Biochem. J., 371, 199-204, 2003).
It is frequently the case that the most potent inhibitor is not the
most suitable inhibitor for therapeutic purposes.
TABLE-US-00001 Inhibitor con- Top 5 kinases inhibited centration
kinase and residual activity ML-9 MSK-1 ROCK-II SmMLCK S6K1 CDK2
100 .mu.M 14% 23% 25% 27% 38% LY PI3K CK2 PHK GSK3.beta. SGK 294002
13% 18% 44% 53% 72% 50 .mu.M HA1077 ROCK-II PRK2 MSK1 S6K1 PKA 20
.mu.M 7% 15% 19% 32% 35% PP2 LCK CDK2 CK1 SAPK2a MKK1 10 .mu.M 1%
3% 6% 21% 55% Ro-31- MAPKAPK1b MSK1 PKC.alpha. GSK3.beta. S6K1 8220
2% 2% 3% 5% 6% 1 .mu.M MSK-1 = mitogen and stress activated protein
kinase 1; ROCK-II = Rho associated coiled coil forming protein
kinase II; SmMLCK = smooth myosin light chain kinase; S6K1 = p70 S6
kinase; CDK2 = cyclin dependant kinase 2; PI3K = phosphoinositide 3
kinase; CK2 = casein kinase 2; PHK = phosphorylase kinase;
GSK3.beta. = glycogen synthetase kinase 3.beta.; SGK = serum and
glucocortin induced kinase; PRK2 = PKC related kinase 2; PKA =
protein kinase A; LCK = T cell specific kinase; CK1 = casien kinase
1; SAPK2a = p38 kinase; MKK1 = mitogen activated protein kinase 1;
MAPKAP-K1b = mitogen activated protein kinase activated protein
kinase 1b; PKC.alpha. = protein kinase C alpha.
[0010] It will be clearly understood that, if a prior art
publication is referred to herein, this reference does not
constitute an admission that the publication forms part of the
common general knowledge in the art in Australia or in any other
country.
SUMMARY OF THE INVENTION
[0011] Using the axioms of this drug discovery methodology, we
synthesised several novel classes of chemotypes in an effort to
develop drug candidates against kinase targets.
[0012] Kinases selected examples from the three different classes;
serine/threonin kinase, tyrosine receptor kinase and tyrosine
non-receptor kinase have been explored to determine the generality
of the current invention. Compounds were tested within the industry
standard concentration range described above and have revealed
potent and selective inhibitors against each selected kinase
target.
[0013] It is a general object of the invention to provide compounds
suitable for the treatment of disorders mediated by protein kinase
activity and in the treatment of the above mentioned disorders.
[0014] It is an optional object of the invention to provide a
pharmaceutical formulation comprising at least one compound as
described herein or a pharmaceutically acceptable salt thereof,
together with one or more pharmaceutically acceptable carriers,
diluents or excipients.
[0015] It is a further optional object of the invention to provide
a method of treatment of a human or animal subject suffering from a
disorder mediated by aberrant protein kinase activity which method
comprises administering to the human or animal subject an effective
amount of a compound as described herein or a pharmaceutically
acceptable salt thereof.
[0016] It is a further object of the invention to prepare novel
compounds per se [0017] In one form, the invention comprises method
of inhibiting or effecting protein kinase activity which comprises
contacting a protein kinase with a compound of formula I being a
derivative of a furanose or pyranose form of a monosaccharide, or a
pharmaceutically acceptable derivative thereof
[0017] ##STR00001## [0018] Wherein; [0019] n is 1 or 2, [0020] X is
selected from the group consisting of: OR1, an unsubstituted 5 or 6
membered heterocyclic moiety, a substituted 5 or 6 membered
heterocyclic moiety, an unsubstituted 9 or 10 membered
heterobicyclic moiety and a substituted 9 or 10 membered
heterobicyclic moiety, [0021] R1 is selected from the group
consisting of: C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl,
C1 to C7 heteroalkyl, C6 to C14 aryl, C3 to C14 heteroaryl, C6 to
C14 arylalkyl and C3 to C14 heteroarylalkyl, [0022] Y is selected
from the group consisting of: an unsubstituted 5 or 6 membered
heterocyclic moiety; a substituted 5 or 6 membered heterocyclic
moiety, an unsubstituted 9 or 10 membered heterobicyclic moiety and
a substituted 9 or 10 membered heterobicyclic moiety; an amino
acid, a dipeptide, and
[0022] ##STR00002## [0023] R6 is selected from the group consisting
of: H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7
heteroalkyl, C.sub.6 to C.sub.14 aryl, C.sub.3 to C.sub.14
heteroaryl, C.sub.6 to C.sub.14 arylalkyl or C.sub.3 to C.sub.14
heteroarylalkyl, [0024] with the proviso that R6, R7 and R8 are not
all H, [0025] R9 is selected from H, or --(CO)--R6, [0026] R7, R8,
R11, R12, R14, are independently selected from the group consisting
of: H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7
acyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C6 to C14 arylacyl, C6
to C14 heteroaryl, C6 to C14 heteroarylacyl, C6 to C14 arylalkyl
and C6 to C14 heteroarylalkyl, [0027] R13 is selected from the
group consisting of: unsubstituted phenyl unsubstituted benzyl,
substituted phenyl, substituted benzyl, H, C1 to C7 alkyl, C1 to C7
alkenyl, C1 to C7 alkynyl, C1 to C7 acyl, C1 to C7 heteroalkyl, C6
to C14 aryl, C6 to C14 arylacyl, C6 to C14 heteroaryl, C6 to C14
heteroarylacyl, C6 to C14 arylalkyl or C6 to C14 heteroarylalkyl,
--S--R6 and --O--R6, [0028] R15 is absent or is at least one
substituent on the aromatic ring which are independently selected
from the group consisting of: OH, NO, NO.sub.2, NH.sub.2, N.sub.3,
halogen, CF.sub.3, CHF.sub.2, CH.sub.2F, nitrile, alkoxy, aryloxy,
amidine, guanidiniums, carboxylic acid, carboxylic acid ester,
carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl,
aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl,
substituted or unsubstituted imine, sulfate, sulfonamide,
phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid,
heteroaryloxy, alkyl, aminoaryl, aminoheteroaryl, thioalkyl,
thioaryl and thioheteroaryl. [0029] R1 may be substituted, cyclic
or acyclic, branched and/or linear. [0030] R7 and R8 may combine to
form a cyclic structure. [0031] R6 and one of R7 or R8 may combine
to form a cyclic structure. [0032] R11 and R12 may combine to form
a cyclic structure, [0033] X may be selected from: OR1,
[0033] ##STR00003## [0034] R1 and R3 are independently selected
from the group consisting of C1 to C7 alkyl, C1 to C7 alkenyl, C1
to C7 alkynyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C3 to C14
heteroaryl, C6 to C14 arylalkyl and C3 to C14 heteroarylalkyl,
[0035] R4 is selected from the group consisting of: H, C1 to C7
alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7 heteroalkyl, C6
to C14 aryl, C3 to C14 heteroaryl, C6 to C14 arylalkyl and C3 to
C14 heteroarylalkyl, [0036] R5 is selected from the group
consisting of: H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7
alkynyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C3 to C14
heteroaryl, C6 to C14 arylalkyl or C3 to C14 heteroarylalkyl, C1 to
C7 acyl, C6 to C14 arylacyl, and C3 to C14 heteroarylacyl, [0037]
R2 is selected from the group consisting of: --(C.dbd.O)--R3,
--(C.dbd.O)--OR4, and --(C.dbd.O)--NH--R4, [0038] Y is selected
from:
[0038] ##STR00004## [0039] At least one of R1-R14 may be
substituted and these substituents and the substituents on the
substituted 5 or 6 membered heterocyclic moiety and the substituted
9 or 10 membered heterobicyclic moiety may be selected from the
group consisting of: OH, NO, NO.sub.2, NH.sub.2, N.sub.3, halogen,
CF.sub.3, CHF.sub.2, CH.sub.2F, nitrile, alkoxy, aryloxy, amidine,
guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic
acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl,
aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or
unsubstituted imine, sulfate, sulfonamide, phosphate,
phosphoramide, hydrazide, hydroxamate, hydroxamic acid,
heteroaryloxy, aminoalkyl, alkyl, aminoheteroaryl, thioalkyl,
thioaryl or thioheteroaryl, which may optionally be further
substituted. [0040] X may comprise
[0040] ##STR00005## [0041] X may comprise
[0041] ##STR00006## [0042] X may comprise --OR1 [0043] Y may
comprise A as described above. [0044] Y may comprise B as described
above. [0045] Y may comprise C as described above. [0046] Y may
comprise D as described above. [0047] Y may comprise E as described
above. [0048] Y may describe F as described above. [0049] Y may
comprise G as described above. [0050] The protein kinase may
comprise a serine or threonine kinase. [0051] The protein kinase
may comprise a tyrosine kinase. [0052] The protein kinase may
comprise one or more of the isoforms of protein kinase C. [0053]
The protein kinase may comprise Tie-2, also known as TEK, HPK-6,
TIE-2 VMCM, VMCM1. [0054] The protein kinase may comprise c-Kit
also known as SCFR, CD117, PBT. [0055] The protein kinase may
comprise VEGF-R2/KDR also known as VEGFR2, VEGFR-2, VEGFR, Hs.KDR,
Hs.12337, FLK1, FLK-1. [0056] The protein kinase may comprise EGF-R
also known as ERBB1, ERBB, EGFRvIII. [0057] The protein kinase may
comprise Abl also known as c-ab1, c-ABL, JTK7, p150, ABL1. [0058]
The protein kinase may comprise MET also known as HGFR, C-MET,
RCCP2. [0059] The protein kinase may comprise, CDK2 also known as
p34CDK2, p33CDK2, p33CDK2. [0060] The protein kinase may comprise
PDGF also known as PDGFR1, PDGFR, PDGF-R-beta, JTK12, CD140B,
PDGFRB. [0061] The protein kinase may comprise kinase, FGFR-1 also
known as N-SAM, LOC51033, FLT2, FLJ14326, CEK, C-FGR, BFGFR, H5,
H4, H3, H2, FLG. [0062] The protein kinase may comprise P38 MAP
Kinase also known as p38alpha p38ALPHA, SAPK2a, SAPK2A, PRKM15,
PRKM14, Mxi2, MXI2, Exip, EXIP, CSPB1, CSBP2, CSBPI, p38, RK, P38,
MAPK14. [0063] In another form, the invention comprises a compound
of formula I which is a derivative of a furanose form of a
monosaccharide of general formula I,
[0063] ##STR00007## [0064] Wherein; [0065] n is 1, [0066] X is
selected from: OR1,
[0066] ##STR00008## [0067] R1 and R3 are independently selected
from the group consisting of: C1 to C7 alkyl, C1 to C7 alkenyl, C1
to C7 alkynyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C3 to C14
heteroaryl, C6 to C14 arylalkyl and C3 to C14 heteroarylalkyl,
[0068] R4 is selected from the group consisting of: H, C1 to C7
alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7 heteroalkyl, C6
to C14 aryl, C3 to C14 heteroaryl, C6 to C14 arylalkyl and C3 to
C14 heteroarylalkyl, [0069] R5 is selected from the group
consisting of: H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7
alkynyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C3 to C14
heteroaryl, C6 to C14 arylalkyl or C3 to C14 heteroarylalkyl, C1 to
C7 acyl, C6 to C14 arylacyl, and C3 to C14 heteroarylacyl, [0070]
R2 is selected from --(C.dbd.O)--R3, --(C.dbd.O)--OR4,
--(C.dbd.O)--NH--R4, [0071] Y is selected from the group consisting
of:
[0071] ##STR00009## [0072] R6 is selected from the group consisting
of H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7
heteroalkyl, C.sub.6 to C.sub.14 aryl, C.sub.3 to C.sub.14
heteroaryl, C.sub.6 to C.sub.14 arylalkyl and C.sub.3 to C.sub.14
heteroarylalkyl, [0073] with the proviso that R6, R7 and R8 are not
all H, [0074] R9 is selected from H, or --(CO)--R6, [0075] R7, R8,
R11, R12, R14, are independently selected from the group consisting
of: H, C1 to C7 alkyl, C1 to C7 alkenyl, C1 to C7 alkynyl, C1 to C7
acyl, C1 to C7 heteroalkyl, C6 to C14 aryl, C6 to C14 arylacyl, C6
to C14 heteroaryl, C6 to C14 heteroarylacyl, C6 to C14 arylalkyl or
C6 to C14 heteroarylalkyl, [0076] R13 is selected from the group
consisting of: unsubstituted phenyl, unsubstituted benzyl,
substituted phenyl, substituted benzyl, H, C1 to C7 alkyl, C1 to C7
alkenyl, C1 to C7 alkynyl, C1 to C7 acyl, C1 to C7 heteroalkyl, C6
to C14 aryl, C6 to C14 arylacyl, C6 to C14 heteroaryl, C6 to C14
heteroarylacyl, C6 to C14 arylalkyl or C6 to C14 heteroarylalkyl,
--S--R6 or --O--R6, [0077] R15 is absent or is at least one
substituent on the aromatic ring which is independently selected
from the group consisting of: OH, NO, NO.sub.2, NH.sub.2, N3,
halogen, CF.sub.3, CHF.sub.2, CH.sub.2F, nitrile, alkoxy, aryloxy,
amidine, guanidiniums, carboxylic acid, carboxylic acid ester,
carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl,
aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl,
substituted or unsubstituted imine, sulfate, sulfonamide,
phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid,
heteroaryloxy, alkyl, aminoaryl, aminoheteroaryl, thioalkyl,
thioaryl or thioheteroaryl. [0078] R7 and R8 may combine to form a
cyclic structure. [0079] R6 and one of R7 or R8 may combine to form
a cyclic structure. [0080] R11 and R12 may combine to form a cyclic
structure. [0081] R1, R2, R3, R4 and R5 are optionally substituted,
cyclic or acyclic, branched and/or linear. [0082] R2 and R3 may
combine to form a ring structure. [0083] R4 and R5 may combine to
form a ring structure. [0084] At least one of R1 to R5 may be
substituted with a substituent selected from the group, OH, NO,
NO.sub.2, NH.sub.2, N.sub.3, halogen, CF.sub.3, CHF.sub.2,
CH.sub.2F, nitrile, alkoxy, aryloxy, amidine, guanidiniums,
carboxylic acid, carboxylic acid ester, carboxylic acid amide,
aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl,
aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or
unsubstituted imine, sulfate, sulfonamide, phosphate,
phosphoramide, hydrazide, hydroxamate, hydroxamic acid,
heteroaryloxy, alkyl, aminoaryl, aminoheteroaryl, thioalkyl,
thioaryl or thioheteroaryl, which may optionally be further
substituted, [0085] X may be
##STR00010##
[0085] or --OR1.
[0086] Y may comprise A as described above. [0087] Y may comprise B
as described above. [0088] Y may comprise C as described above.
[0089] Y may comprise D as described above. [0090] Y may comprise E
as described above. [0091] Y may comprise F as described above.
[0092] Y may comprise G as described above.
[0093] The compounds of the invention may be mixed with a
pharmaceutical acceptable carrier, adjuvant, or vehicle which may
comprise a-toxic carrier, adjuvant, or vehicle that may be
administered to a patient, together with a compound of this
invention, and which does not destroy the pharmacological activity
thereof.
[0094] The pharmaceutical derivative may comprise a salt, ester,
salt of an ester or other derivative of a compound of this
invention which, upon administration to a recipient, is capable of
providing, either directly or indirectly, a compound of this
invention, although no limitation is meant thereby.
[0095] Compounds of the invention may be administered orally such
as by means of a tabled, powder, liquid, emulsion, dispersion and
the like; by inhalation; topically such as by means of a cream,
ointment, salve etc; and as a suppository, although no limitation
is meant thereby.
BEST MODE
General Methods
[0096] General Method 1--Amide bond formation: To a solution of an
acid in DMF (0.3 ml, 0.35 M, 1.0 equiv.) at room temperature was
added a solution of HBTU in DMF (0.3 ml, 0.42 M, 1.2 equiv.)
followed by DIPEA (2.5 equiv.). After 10 min., a solution of the
desired amine in DMF (0.3 ml, 0.37 M, 1.05 equiv.) was added. The
resulting solution was stirred at room temperature for 2.5 h, then
diluted with DCM (8 ml) and washed with 10% citric acid (2.times.5
ml), saturated NaHCO.sub.3 (2.times.5 ml), brine (5 ml) and water
(5 ml). The solvent was removed in vacuo.
[0097] General Method 2--Ester Hydrolysis: A solution of the ester
(0.1 mmoles) in THF (0.5 ml) was treated with a solution of lithium
hydroxide in water (0.5 ml, 0.45 M, 2.1 equiv.). The resulting
mixture was stirred at room temperature overnight, then evaporated
to dryness under reduced pressure to provide the corresponding
carboxyllic acid as the lithium salt. The residue is redissolved in
either ethyl acetate or dichloromethane and washed with a small
quantity of 10% citric acid solution, followed by drying of the
organic layer and removal of the solvents in vacuo to yield the
desired carboxylic acid. In cognate experiments sodium hydroxide or
potassium hydroxide has been substituted for lithium hydroxide to
for the corresponding sodium or potassium salts in comparable
yields. Methanol and dioxane have been substituted for THF as the
reaction solvent with comparable results.
[0098] General Method 3a--Removal of acid labile protecting groups
(isopropylidene and BOC)--solution phase: The compound was
dissolved in acetonitrile and treated with 90/10 trifluoroacetic
acid-water (2 ml) and monitored by t.l.c for reaction completeness.
Reaction times vary considerably from 15 minutes at RT to 6 hours
at RT. When complete, the mixture was concentrated under reduced
pressure and co-evaporating from acetonitrile. The crude products
were resuspended in water-acetonitrile and lyophilised then
purificated by reverse phase C-18 HPLC using a solvent gradient of
water/acetonitrile to afford the desired product as white solids.
In cognate experiments, 50/50 trifluoroacetic acid--water has been
used with similar efficiency.
[0099] General Method 3b--Removal of acid labile protecting groups
(isopropylidene and BOC) and cleavage from resin--solid phase: The
resin bound compound (approx. 200 mg of resin) was washed with DCM
(2.times.2 mL) then treated with TFA/DCM 1:1 (1 mL) for 15 mins.
The resin was filtered and washed with acetonitrile (1 ml)
(filtrates collected). This procedure was repeated for a second
cycle. The filtrates were evaporated under a stream of nitrogen.
The residue was redissolved in water (1 ml) and agitated for 3 h.
After this time, the solution was lyophilised to afford the crude
products which were purified as described above.
[0100] General Method 4--removal of an Fmoc protecting group: The
Fmoc protected compound on resin (12 g of resin, 0.7 mmol/g, 8.4
mmol) was washed with DMF (2.times.120 ml), then treated with 20%
piperidine in DMF (120 ml) and shaken at r.t. for 30 min. The resin
was drained and washed with DMF (2.times.120 ml). The reaction was
repeated and the resin was drained, washed with DMF (2.times.120
ml), DCM (2.times.120 ml), MeOH (2.times.120 ml) and ether
(2.times.120 ml), and dried in vacuo for 2 h.
[0101] General Method 5--coupling of fluoro-nitro-benzoic acid:
Resin bound substrate was washed under N.sub.2 with dry DCM
(1.times.80 ml, 1.times.60 ml). To a solution of
4-fluoro-3-nitrobenzoic acid (9.3 g, FW 185.09, 50.2 mmol, 6
equiv.) in dry DCM (60 ml) and dry DMF (9 ml) at r.t. and under
N.sub.2 was added 1,3-diisopropylcarbodiimide (DIC, 3.9 ml, d
0.806, FW 126.20, 24.9 mmol, 3 equiv.). The solution was stirred
for 10 min., then added to the resin followed by
4-(dimethylamino)pyridine (DMAP, 102 mg, FW 122.17, 0.83 mmol, 0.1
equiv.). The resin was then shaken at r.t. for 3 h, drained, washed
with DMF (4.times.120 ml), DCM (3.times.120 ml) and ether
(2.times.120 ml), and dried in vacuo overnight. The coupling
procedure may be repeated in the event of a positive ninhydrin
test.
[0102] General Method 6--nucleophillic aromatic displacement: Resin
bound 3-nitro-4-fluoro-benzoate XI (200 mg, 0.14 mmol) was washed
under N.sub.2 with dry DMF (2 ml) or dry DMSO (2 ml), then treated
with a solution of the nucleophile (0.42 mmol, 3 equiv.) and
diisopropylamine (DIPEA, 0.146 ml, d 0.742, FW, 129.25, 0.84 mmol,
6 equiv.) in dry DMF (2 ml) or dry DMSO (2 ml) and shaken at r.t.
o/n. The resin was drained and washed with DMF (3.times.2 ml) and
DCM (3.times.2 ml). In the case of DMSO as solvent, the reaction
was warmed to 60 oC. The nucleophile may be any suitable primary or
secondary aliphatic or aromatic amine, or a thiol. In an
alternative experiment, the nucleophile was bound to the solid
support and treated with an excess of ortho-fluoro-nitrobenzyl
derivatives under similar conditions.
[0103] General Method 7--reduction of an aromatic nitro group: The
resin bound substrate (0.14 mmol) was washed with DMF (2.times.2
ml) and then suspended in DMF (0.7 ml) to which was added a
solution of SnCl.sub.2.2H.sub.2O in DMF (0.7 ml, 2 M, 1.40 mmol, 10
equiv.). The resin was shaken at r.t. o/n, then washed with DMF
(5.times.2 ml), DCM (3.times.2 ml) and MeOH (5.times.2 ml).
[0104] General Method 8 preparation and reaction of an acid
chloride: Resin bound substrate (0.14 mmol) was washed with DCM
(2.times.2 ml) and then under N.sub.2 with dry DCM (2.times.2 ml).
A suspension of the of sugar-acid building blocks (0.42 mmol, 3
equiv.) in dry DCM (2 ml) was treated with triphosgene (42 mg, FW
296.75, 0.14 mmol, 1 equiv.) followed by collidine (0.159 ml, d
0.917, FW 121.18, 1.20 mmol, 8.6 equiv.). An effervescence was
observed and a solution formed. After 1 min., this solution was
added to the resin bound substrate and the resin was shaken at r.t.
for 3 h. The resin was drained and washed with DCM (5.times.2 ml)
and MeOH (3.times.2 ml).
[0105] General Method 9 cleavage of adenosine N-benzoyl group: The
adenosine-containing products were treated with saturated ammonia
in methanol (4 ml) at r.t. o/n. The solvent was removed in vacuo
and the product was again treated with sat NH.sub.3 in MeOH at r.t.
o/n. The solvent was removed in vacuo and compounds purified as
described above. In an alternative procedure, 1M hydrazine hydrate
in DMF was substituted for methanolic ammonia. The latter procedure
is particularly useful for benzoate removal on solid support.
[0106] General Method 10--benzimidazole synthesis: Resin bound
substrate (approx. 200 mg, 0.14 mmol) was treated with a solution
of an aldehyde (5.0 equivalents) in N-methylpyrrolidine (NMP) (4
ml) and heated to 45-50.degree. C. overnight. The resins were
subsequently washed with DMF (3.times.4 mL), DCM (3.times.4 mL),
MeOH (3.times.4 mL), ether (3.times.4 mL) and dried in vacuo
overnight.
[0107] General Method 11--Cesium carboxylate coupling: The cesium
salt of the Boc protected amino acid is made by dissolving the
amino acid in methanol (5 ml/mmol) and water (0.5 ml/mmol) and
adding an aqueous solution of 20% Cs.sub.2CO.sub.3 until pH 7 is
reached. The solvent is removed in vacuo and the material is
freeze-dried overnight to give a white powder. The resin is treated
with the cesium salt (5 eq) in dry DMF (4 ml/g of resin) and
stirred at 50.degree. C. for 24 hours. The resin is drained and
washed with DMF, DMF/H.sub.2O (1:1; .times.3), MeOH/H.sub.2O (1:1;
.times.3) and MeOH (.times.3) and then dried in vacuo.
[0108] General Method 12--Reductive amination: 6 eq of aldehyde is
dissolved in TMOF/THF (1:1; 2 ml) and added to the resin (200 mg)
and shaken at room temperature for 34 hours. The resin is drained
and a solution of NaCNBH.sub.3 (2 eq) in THF/MeOH/AcOH (9:1:0.1; 2
ml) is added to the resin and shaken overnight at room temperature.
The resin is then drained and washed with THF/MeOH (1:3; .times.3,
DMF/MeOH (1:3; .times.3), DCM/MeOH (1:3; .times.3) and DCM.
[0109] General Method 13--Urea formation: In a gloved box, the
resin is swelled in 10% DIPEA/DCM, a solution of triphosgene (2 eq
in 1.2 ml of dry DCM) was added to the resin in two batches and
shaken for 1 hour. The resin is washed with dry DCM (1 ml.times.2)
and a solution of the amine (1.1 eq) and DIPEA (2.2 eq) in 1.5 ml
of dry DCM was added and shaken for 30 minutes. The resin is
drained and washed with DMF (.times.3), DCM (.times.3) and MeOH
(.times.3) and dried.
[0110] General Method 14 base catalysed ring closure: The resin was
treated with a solution of MeOH/NEt.sub.3 (9:1; 2 ml) and heated to
60.degree. C. overnight. The resin is drained (collecting the
filtrate) and washed with MeOH, (1 ml), DCM (1 ml), MeOH (1 ml) and
DCM (1 ml). The filtrates are combined and the solvent removed in
vacuo. The process is then repeated.
[0111] General Method 15--Thiourea formation: Resin bound substrate
was washed under N.sub.2 with dry THF (3.times.30 mL) then
thiocarbonyl diimidazole (2.49 g, 14 mmol) in dry THF (70 mL,
conc=0.2M) was added and the resin was shaken at rt for 12 h. The
resin was filtered, washed with THF (3.times.30 mL), DMF
(2.times.30 mL), DCM (2.times.30 ml), DCM/MeOH (30 mL), MeOH (30
mL) and dried in vacuo.
[0112] General Method 16--S alkylation of an isothiourea: The
reactions were performed in Bodhan Miniblocks. The resin bound
thiourea compound resin (200 mg) was washed under N.sub.2 with dry
DMF (2.times.2 mL). Alkyl halide R.sup.1X (0.7 mmol) in dry DMF (1
mL) was added followed by DIPEA (1.4 mmol) in dry DMF (1 mL). The
resin was shaken at rt for 12 h, then washed with DMF (3.times.2
mL), DCM (3.times.2 mL), DCM/MeOH 1:1 (2.times.2 mL), MeOH
(2.times.2 mL).
[0113] General Method 17--bromoacetylation: To bromoacetic acid
(7.76 g) in dry DCM (40 mL) was added slowly DIC (4.4 mL) at
0.degree. C. The solution was stirred at 0.degree. C. for 30 mins.
The solution was syringed out leaving the precipitated urea.
[0114] Resin bound substrate was washed under N.sub.2 with dry DMF
then swollen in dry DMF (1 mL). The bromoacetic anhydride solution
in dry DCM (1 ml) was added and the resin was shaken at rt for 1
hrs. The resin was filtered, washed with dry DMF (3.times.3 mL)
under N.sub.2 (glove box) and dry DCM (2.times.3 mL). Excess DCM
was drained applying positive pressure of N.sub.2. The resin was
carried through the next step immediately.
[0115] General Method 18--N-alkylation: Bromoacetylated resin
produced by general method 17 is added to a sugar amine building
block (5 eq) in DMF (1 mL). The resin was shaken at rt for 16 h
then filtered, washed with DMF, DCM, DCM/MeOH and dried in
vacuo.
[0116] General Method 19-Dichloro-Nitropyrimidine addition: The
resin was swelled in NMP and a solution of
4,6-Dichloro-5-nitropyrimidine (5 eq) and DIPEA (10 eq) in NMP (1
ml/100 mg resin) was added and shaken at room temperature overnight
(solution turned deep orange-red). The resin was drained under
nitrogen and washed with dry DMF and dry DCM until filtrate is
colourless and dried in vacuo.
[0117] General Method 20--Nitro reduction: The resin was swelled in
DCM (1.5 ml/100 mg) and a solution of K.sub.2CO.sub.3 (10 eq) and
Na.sub.2S.sub.2O.sub.4 (8 eq) in H.sub.2O (0.75 ml/100 mg) was
added. Viologen (0.4 eq) was then added turning the solution deep
blue. The resin was then shaken vigourously for 72 hours. The resin
was then drained and washed with an aqueous solution of 1% AcOH,
THF, DMF and DCM and dried in vacuo.
[0118] General Method 21--Aldehyde cyclisation: A solution of the
aldehyde (5 eq) in NMP with 1% AcOH (800 .mu.l/100 mg resin) was
added to the dry resin in a test tube. The tube was sealed but
allowed to vent with a needle in the top. The resin was heated at
100.degree. C. overnight. The resin was filtered and washed with
DMF, DCM and MeOH and dried in vacuo.
[0119] General Method 22--Acid Chloride Acylation:
[0120] Resin bound substrate was washed under N.sub.2 with dry DCM
then swollen in DIPEA (20 eq)/DCM (1 mL). A solution of acid
chloride (10 eq) in DCM (1 ml) was added and the resin was shaken
at rt for 24 h. The resin was washed with DMF, DMF/MeOH, DCM,
DCM/MeOH, MeOH and dried in vacuo.
[0121] General Method 23--Reaction with the isocyanates and the
resin cleavage: The resin was taken up in DCE and cooled to
0.degree. C. followed by isocyanate (4 eq) addition. After 30
minutes, 10% TFA/DCM was added followed by shaking for 1 hour at
room temperature. The resin was filtered and washed with DCM. The
filtrate was concentrated under reduced pressure to afford the
crude residue.
[0122] General Method 24--Biological assays:
[0123] Compounds were tested in vitro as follows.
[0124] Recombinant protein kinases, which were expressed as fusion
proteins in SF9 insect cells or E. coli, were used for all in vitro
assays. The purity and identity of each kinase was checked by
SDS-PAGE/silver staining and by western blot analysis with specific
antibodies.
[0125] All kinase assays except for p38a (see below) were performed
in 96-well micro-titre plates. The assay components included assay
buffer, ATP, test compound, enzyme and substrate.
[0126] The assay for all enzymes (except for the PKq see below
contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl.sub.2, 3 mM
MnCl.sub.2, 3 .mu.M Na-orthovanadate, 1 mM DTT, 0.1 .mu.M
[.gamma.-.sup.33P]-ATP (approx. 5.times.10.sup.5 cpm per well).
[0127] The assay for the PKCs contained 60 mM HEPES-NaOH, pH 7.5, 1
mM EDTA, 1.25 mM EGTA, 5 mM MgCl.sub.2, 1.32 mM CaCl.sub.2, 5
.mu.g/ml Phosphatidylserine, 1 .mu.g/ml 1.2 Dioleyl-glycerol, 1.2
mM DTT, 50 .mu.g/ml PEG.sub.20000, 0.1 .mu.M [.gamma.-.sup.33P]-ATP
(approx. 5.times.10.sup.5 cpm per well).
[0128] The table below details the amounts of enzyme and substrate
that were used per well:
TABLE-US-00002 Screen- Enzyme Substrate # Kinase pool # (ng/50
.mu.l) Substrate (ng/50 .mu.l 1 KIT 1 50 Poly(Glu, Tyr).sub.4:1 125
2 EGF-R 4 50 Poly(Glu, Tyr).sub.4:1 125 3 TIE2 3 100 Poly(Glu,
Tyr).sub.4:1 125 4 PDGF- 3 100 Poly(Glu, Tyr).sub.4:1 500 Ralpha 5
FGF-R1 1 75 Poly(Glu, Tyr).sub.4:1 500 6 CDK2/CycA 2 10 Histone H1
250 7 MET 7 100 Poly(Glu, Tyr).sub.4:1 125 8 VEGF-R2 2 50 Poly(Glu,
Tyr).sub.4:1 125 9 ABL 1 10 Poly(Ala, Glu, Lys, 250
Tyr).sub.6:2:5:1 10 PKC-beta1 1 13 Histone H1 500
[0129] The reaction cocktails were incubated at 30.degree. C. for
80 minutes. The reaction was stopped with 50 .mu.l of 2% (v/v)
H.sub.3PO.sub.4, plates were aspirated and washed twice with 200
.mu.l of H.sub.2O or 0.9% (w/v) NaCl. Incorporation of
.sup.33P.sub.i was determined with a microplate scintillation
counter.
[0130] The mitogen-activated protein kinase p38a assays were done
in a proprietary microassay NanoCarrier.TM. 2080 format. In these
assays phosphorylation was detected by a phospho-substrate specific
monoclonal antibody in an indirect competition assay. The degree of
binding of the antibody to the phospho-substrate was measured by
fluorescence polarization using 2D-FIDA anisotrophy. In these
experiments the final concentration of the enzyme was 1.6 nM and
the substrate was 2 .mu.M.
[0131] All data is presented as residual activity, which is the
activity of the enzyme in the presence of the stipulated
concentration of inhibitor or compound. 100% activity is the
maximum activity of the enzyme in the absence of any inhibitor or
compound.
[0132] In all experiments the Z' value was calculated according to
Zhang et al (J-H Zhang, T. D. Y Chung, K. R. Oldenburg (1999)
Journal of Biomolecular Screening 4:67-73) using the standard
deviations and mean values of the positive and negative
controls.
Z'=1-(3*Stdev.sub.neg+3*Stdev.sub.pos)/(Mean.sub.pos-Mean.sub.neg)
Only data where the Z' value was >0.5 was used.
EXAMPLE 1
##STR00011##
[0133] Analysis of Some Typical Example Compounds
##STR00012##
[0135] Isomer A: proton (400 MHz: DMSO) 2.38 (dt, J 5.0, 6H,
CH.sub.2CH.sub.2), 2.65 (d, J 15.0 Hz, 1H, CH.sub.3), 3.85-3.95 (m,
2H, H2 or H3 or H4), 4.05 (dd, J 3.0, 8.0 Hz, 1H, H5a), 4.10 (dd, J
3.0, 8.0 Hz, 1H, H5b), 4.30 (m, 1H, CH), 4.65 (dd, J 5.0, 5.0 Hz,
1H, H2 or H3 or H4), 5.87 (d, J 4.0 Hz, 1H, H1), 8.30 (s, 1H, ArH),
8.45 (s, 1H, ArH).
[0136] Isomer B: proton (400 MHz: DMSO) 2.42 (dt, J 5.0, 6H,
CH.sub.2CH.sub.2), 2.75 (d, J 15.0 Hz, 1H, CH.sub.3), 3.85-3.95 (m,
2H, H2 or H3 or H4), 4.05 (dd, J 3.0, 8.0 Hz, 1H, H5a), 4.10 (dd, J
3.0, 8.0 Hz, 1H, H5b), 4.30 (m, 1H, CH), 4.65 (dd, J 5.0, 5.0 Hz,
1H, H2 or H3 or H4), 5.92 (d, J 4.0 Hz, 1H, H1), 8.35 (s, 1H, ArH),
8.50 (s, 1H, ArH).
EXAMPLE 2
##STR00013##
[0137] Analysis of Some Typical Example Compounds
##STR00014##
[0139] proton (400 MHz: D.sub.2O) 2.36-2.55 (m, 5H, alkyl H),
2.57-2.76 (m, 1H, alkyl H), 3.31-3.48 (m, 2H, H5), 3.98-4.07 (m,
1H, H4), 4.45-4.56 (m, 2H, H3, NCHCO), 4.69-4.75 (m, 2H, H2), 5.57
(d, J=2.4 Hz, 1H, H1), 7.32-7.40 (m, 2H, PhH), 7.41-7.53 (m, 3H,
PhH).
##STR00015##
[0140] proton (400 MHz: D.sub.2O) 2.26-2.40 (m, 4H, alkyl H), 2.73
(dd, J 14.0, 8.0 Hz, 1H, CHaPh), 2.88 (dd, J 14.0, 6.2 Hz, 1H,
CHbPh), 3.30 (dd, J 14.6, 4.6 Hz, 1H, H5a), 3.42 (dd, J 14.6, 3.8
Hz, 1H, H5b), 3.96-4.02 (m, 1H, H4), 4.26 (t, J 5.8 Hz, 1H, H3),
4.36 (t, J 7.4 Hz, 1H, NCHCO), 5.52 (d, J 2.8 Hz, 1H, H1),
7.02-7.20 (m, 5H, PhH), 7.35 (d, J 6.4 Hz, 2H, PhH), 7.42-7.54 (m,
3H, PhH).
##STR00016##
[0141] proton (400 MHz: D.sub.2O) 1.76-1.87 (m, 1H, alkyl H),
1.96-2.08 (m, 1H, alkyl H), 2.30-2.41 (m, 6H, alkyl H), 3.43 (d, J
4.4 Hz, 2H, H5), 4.06 (q, J 5.2 Hz, 1H, H4), 4.26 (dd, J 9.0, 5.2
Hz, 1H, H3), 4.40 (t, J 5.6 Hz, 1H, NCHCO), 4.69-4.74 (m, 1H, H2),
5.54 (d, J 3.2 Hz, 1H, H1), 7.2.8-7.48 (m, 8H, PhH), 7.65 (s, 1H,
PhH).
##STR00017##
[0142] proton (400 MHz: D.sub.2O) 0.77 (t, J 7.4 Hz, 3H,
CH.sub.2CH.sub.3), 1.42-1.56 (m, 2H, CH.sub.2CH.sub.3), 2.37-2.53
(m, 5H, alkyl H), 2.58 (dd, J 15.4, 5.4 Hz, 1H, alkyl H), 2.89 (t,
J 7.6 Hz, 2H, ArCH.sub.2), 3.30-3.46 (m, 2H, H5), 4.07-4.15 (m, 1H,
H4), 4.42-4.53 (m, 2H, H3, NCHCO), 4.70-4.75 (m, 2H, H2), 5.87 (d,
J 2.8 Hz, 1H, H1).
##STR00018##
[0143] proton (400 MHz: D.sub.2O) 0.78 (t, J 7.2 Hz, 3H,
CH.sub.2CH.sub.3), 1.38-1.46 (m, 2H, CH.sub.2CH.sub.3), 2.34 (bs,
4H, alkyl H), 2.70 (t, J 10.2 Hz, 1H, ArCH.sub.a), 2.74-2.96 (m,
3H, ArCH.sub.b, CH.sub.2Ph), 3.25-3.45 (m, 2H, H5), 4.02-4.12 (m,
1H, H4), 4.18-4.25 (m, 2H, H3), 4.29-4.38 (m, 1H, NCHCO), 5.83 (bs,
1H, H1), 6.99-7.20 (m, 5H, PhH).
##STR00019##
[0144] proton (400 MHz: D.sub.2O) 0.73 (t, J 7.4 Hz, 3H,
CH.sub.2CH.sub.3), 1.36-1.50 (m, 2H, CH.sub.2CH.sub.3), 1.73-1.85
(m, 1H, alkyl H), 1.88-2.03 (m, 1H, alkyl H), 2.28-2.45 (m, 6H,
alkyl H), 2.84 (q, J 7.5 Hz, 2H, ArCH.sub.2), 3.42 (d, J 4.4 Hz,
2H, H5), 4.10-4.20 (m, 2H, H3, H4), 4.38 (t, J 5.4 Hz, 1H, NCHCO),
5.84 (d, J 2.8 Hz, 1H, H1), 7.34-7.52 (m, 3H, ArH), 7.65 (s, 1H,
ArH).
Some Typical Peptide Arms IIa-IIr Used in Step a of Examples 1 and
2
##STR00020## ##STR00021##
[0145] EXAMPLE 3
##STR00022##
[0146] Blocks IX, X and XI
##STR00023##
[0147] Analysis of a Typical Example Compound
##STR00024##
[0149] proton (400 MHz: d.sub.6 DMSO) 4.92 (q, J 4.4 Hz, 1H, H2 or
H3), 4.98 (q, J 5.1 Hz, 1H, H2 or H3), 5.33 (d, J=4.0 Hz, 1H, H4),
5.54 (d, J=16.8 Hz, 1H, CH.sub.aPh), 5.62 (d, J 17.2 Hz, 1H,
CH.sub.bPh), 5.77 (d, J 5.3 Hz, 1H, OH), 5.80 (d, J 5.4 Hz, 1H,
OH), 6.10 (d, J 5.3 Hz, 1H, H1), 6.96 (d, J 7.9 Hz, 1H, PhH), 7.09
(t, J 7.8 Hz, 1H, PhH), 7.24 (bs, 2H, NH.sub.2), 7.27 (bs, 1H,
PhH), 7.2.9 (s, 1H, CONH.sub.a), 7.36 (d, J 8.9 Hz, 1H, PhH), 7.47
(d, J 8.3 Hz, 1H, ArH), 7.78 (dd, J 8.5, 1.6 Hz, 1H, ArH), 7.98
(bs, 2H, ArH, CONH.sub.b), 8.31 (d, J 1.2 Hz, 1H, ArH), 8.37 (s,
1H, ArH).
EXAMPLE 4
##STR00025## ##STR00026##
[0150] Exemplary Aldehydes Used in Step 4-e
[0151] Benzaldehyde, 3-Bromobenzaldehyde, m-Tolualdehyde,
2-Methoxybenzaldehyde, p-Tolualdehyde, 4-Dimethylaminobenzaldehyde,
4-Cyanobenzaldehyde, 1,2,3,6-tetrahydrobenzaldehyde,
Indole-3-carboxaldehyde, 2-naphthaldehyde, 3-methyl
thiophene-2-carboxaldehyde, cyclohexane carboxaldehyde,
pyrrole-2-carboxaldedhyde, phenyl acetaldehyde,
4-(2-pyridyl)benzaldehyde,
.alpha.,.alpha.,.alpha.-trifluoro-o-tolualdehyde,
2,5-dimethylbenzaldeyde, 3,5-difluorobenzaldehyde,
2-fluorobenzaldehyde, 4-fluoro-3-(trifluoromethyl)benzaldehyde.
EXAMPLE 5
##STR00027##
[0152] Analysis of Some Typical Example Compounds
##STR00028##
[0154] proton (400 MHz: d.sub.6 DMSO) 2.41 (s, 3H, CH.sub.3), 3.83
(s, 3H, OCH.sub.3), 4.34-4.53 (m, 4H, H2, H3, H4, H5a), 4.75 (d, J
13.2 Hz, 1H, H5b), 5.80 (s, 1H, H1), 6.97 (d, J 8.8 Hz, 2H, ArH),
7.39-7.47 (m, 2H, ArH), 7.51 (bs, 1H, NHa), 7.57-7.67 (m, 3H, ArH),
7.69-7.75 (m, 1H, ArH), 7.79 (bs, 1H, NHb).
##STR00029##
[0155] proton (400 MHz: d.sub.6 DMSO) 0.77 (t, J 7.4 Hz, 3H,
CH.sub.2CH.sub.3), 1.40 (q, J 7.1 Hz, 2H, CH.sub.2CH.sub.3), 2.37
(s, 3H, ArCH.sub.3), 2.84-2.98 (m, 2H, ArCH.sub.2), 4.38-4.52 (m,
4H, H2, H3, H4, H5a), 4.70 (bd, J 14.4 Hz, 1H, H5b), 5.80 (s, 1H,
H1), 6.85 (d, J 8.0 Hz, 2H, ArH), 7.27 (bs, 2H, NHa, ArH),
7.48-7.60 (m, 4H, ArH), 7.78 (bs, 1H, NHb).
##STR00030##
[0156] proton (400 MHz: d.sub.6 DMSO) 3.77 (s, 3H, OCH.sub.3),
4.35-4.46 (m, 3H, H2, H3, H4), 4.57 (bdd, J 14.8, 6.4 Hz, 1H, H5a),
4.84 (bd, J 14.8 Hz, 1H, H5b), 5.05 (d, J 11.6 Hz, 1H, OCHa), 5.11
(d, J 11.6 Hz, 1H, OCHb), 5.34 (s, 1H, H1), 6.96-7.04 (m, 4H, ArH),
7.20 (d, J 8.8 Hz, 2H, ArH), 7.30-7.46 (m, 7H, ArH), 7.54 (bs, 1H,
NHa), 7.60 (d, J 8.8 Hz, 2H, ArH), 7.63-7.68 (m, 1H, ArH),
7.71-7.78 (m, 1H, ArH), 7.90 (bs, 1H, NHb).
EXAMPLE 6
##STR00031## ##STR00032##
[0157] EXAMPLE 7
##STR00033## ##STR00034##
[0158] EXAMPLE 8
##STR00035##
[0159] Analysis of Some Typical Example Compounds
##STR00036##
[0160] Isomer 1:
[0161] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.46 (s, 1H,
H-6); 8.26 (d, 1H, H-8); 7.93 (s, 2H, NH.sub.2); 7.37-7.31 (m, 6
h); 7.15-7.08 (m, 5H); 6.92 (d, 1H, J=6 Hz); 5.86 (d, 1H, J=5.6 Hz,
H-1); 4.70-4.64 (m, 2H, containing H-2 and H.sub..beta.1ald); 4.39
(d, 1H, J=16 Hz, H.sub..beta.2ald); 4.20 (t, 1H, J=4.8 Hz,
H.sub..alpha.); 4.04-3.96 (m, 2H, containing H-3, H-5A); 3.59 (d,
1H, J=6.8 Hz, H4); 2.97 (m, 2H, containing H.sub..beta.1,
H.sub..beta.2).
Isomer 2:
[0162] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.42 (s, 1H,
H-6); 8.22 (d, 1H, H-8); 7.75 (s, 2H, NH.sub.2); 7.38-7.30 (m, 6
h); 7.17-7.11 (m, 5H); 6.98-6.96 (m, 1H, J=6 Hz); 5.82 (d, 1H,
J=5.6 Hz, H-1); 4.72-4.64 (m, 2H, containing H-2 and
H.sub..beta.1ald); 4.40 (d, 1H, J=16.4 Hz, H.sub..beta.2ald); 4.21
(t, 1H, J=4.4 Hz, H.sub..alpha.); 4.08 (t, 1H, J=4.4 Hz, H-3); 3.97
(q, 1H, J=6.4, 10.4 Hz, H-5A); 3.65 (dd, 1H, J=6.4, 14.4 Hz, H-4);
3.54 (dd, 1H, J=7.6, 14.4, H-5A); 2.98 (d, 2H, J=4.8 Hz containing
H.sub..beta.1, H.sub..beta.2).
##STR00037##
Isomer 1:
[0163] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.48 (s, 1H,
H-6); 8.27 (s, 1H, H-8); 7.45 (d, 1H, J=4.4 Hz); 7.40 (d, 1H, J=4.8
Hz); 7.24-7.09 (m, 4H); 7.05-7.02 (m, 1H); 6.97-6.91 (m, 2H); 5.84
(d, 1H, J=6.4 Hz, H-1); 4.86 (d, 1H, J=16 Hz, H.sub..beta.1ald);
4.66-4.63 (m, 1H, H-2); 4.45 (d, 1H, J=16 Hz, H.sub..beta.2ald);
4.21 (t, 1H, J=4.4 Hz, H.sub..alpha.); 4.03 (t, 1H, J=3.6 Hz, H-3);
3.98-3.92 (m, 1H, H-5A); 3.19 (q, 1H, J=5.2, 9.2 Hz H.sub..beta.1);
3.05-3.01 (m, 1H, H.sub..beta.2).
Isomer 2:
[0164] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.47 (s, 1H,
H-6); 8.26 (s, 1H, H-8); 7.44 (d, 1H, J=4 Hz); 7.41 (d, 1H, J=4.8
Hz); 7.24-7.09 (m, 4H); 7.05-7.02 (m, 1H); 6.97-6.91 (m, 2H); 5.82
(d, 1H, J=6.4 Hz, H-1); 4.88 (d, 1H, J=16 Hz, H.sub..beta.1ald);
4.66-4.63 (m, 1H, H-2); 4.45 (d, 1H, J=16 Hz, H.sub..beta.2ald);
4.22 (t, 1H, J=4.4 Hz, H.sub..alpha.); 4.06 (t, 1H, J=4 Hz, H-3);
3.98-3.92 (m, 1H, H-5A); 3.22 (q, 1H, J=5.2, 9.2 Hz H.sub..beta.1);
3.05-3.01 (m, 1H, H.sub..beta.2).
##STR00038##
[0165] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.37 (s, 1H,
H-6); 8.12 (s, 1H, H-8); 7.63 (t, 4H, J=8.4 Hz); 7.46 (t, 2H, J=7.6
Hz); 7.36-7.27 (m, 5H); 5.87 (d, 1H, J=5.6 Hz, H-1); 5.53 (d, 1H,
J=6.4 Hz); 5.35 (d, 1H, J=4.8), 4.78 (q, 1H, J=5.2, 10.4 Hz); 4.51
(s, 2H), 4.17-4.08 (m, 2H); 3.92 (s, 2H); 3.82-3.77 (m, 1H);
3.70-3.64 (m, 1H).
##STR00039##
[0166] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 7.78 (s, 1H);
7.42 (s, 1H); 7.08 (d, 1H, J=4 Hz); 6.88 (d, 1H, J=3.6 Hz); 5.77
(d, 1H, J=2.8 Hz); 4.62-4.60 (m, 1H); 4.54 (s, 2H); 4.39 (t, 1H,
J=5.2 Hz); 4.16 (q, 1H, J=6, 11.6 Hz); 3.85 (d, 2H, J=5.2 Hz);
3.62-3.57 (m, 1H); 3.53-3.48 (m, 1H); 3.02-2.90 (m, 3H); 1.54-1.48
(m, 2H); 0.86-0.83 (m, 3H).
##STR00040##
Isomer 1:
[0167] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.40 (s, 1H);
8.18 (s, 1H); 7.62 (s, 2H); 7.56 (d, 2H, J=7.6 Hz); 7.44 (t, 2H,
J=3.6 Hz); 7.37 (t, 3H, J=8.4 Hz); 7.27-7.25 (m, 3H); 7.20-7.18 (m,
2H); 7.08 (d, 2H, J=8 Hz); 5.87 (d, 1H, J=5.6 Hz); 4.76 (d, 1H,
J=15.6 Hz); 4.67 (t, 1H, J=5.6 Hz); 4.30 (d, 1H, J=15.6 Hz); 4.23
(t, 1H, J=4.4 Hz); 4.04-4.00 (m, 2H); 3.70-3.59 (m, 2H); 3.18-3.04
(m, 2H).
Isomer 2:
[0168] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.39 (s, 1H);
8.20 (s, 1H); 7.81 (s, 2H); 7.61 (d, 2H, J=7.2 Hz); 7.52 (d, 2H,
J=8 Hz); 7.45 (t, 3H, J=7.2 Hz); 7.35-7.26 (m, 5H); 7.21 (dd, 4H,
J=6.8, 15.6); 5.83 (d, 1H, J=6 Hz); 4.78 (d, 1H, J=15.6 Hz); 4.69
(t, 1H, J=5.2 Hz); 4.30 (d, 1H, J=15.6 Hz); 4.25 (t, 1H, J=4.4 Hz);
4.11 (t, 1H, J=4.4 Hz); 4.02-3.98 (m, 2H); 3.21-3.06 (m, 2H);
3.18-3.04 (m, 2H).
##STR00041##
Isomer 1
[0169] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.46 (s, 1H);
8.25 (s, 1H); 7.63 (d, 4H, J=7.2 Hz); 7.52 (t, 2H, J=7.6 Hz);
7.44-7.36 (m, 5H); 7.28 (d, 2H, J=8.4 Hz); 7.16 (d, 2H, J=8.4 Hz);
5.95 (d, 1H, J=5.6 Hz); 4.79-4.73 (m, 2H); 4.40-4.33 (m, 2H);
4.13-4.07 (m, 2H); 3.78-3.70 (m, 2H); 3.26-3.11 (m, 2H).
Isomer 2
[0170] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.26 (s, 1H);
8.07 (s, 1H); 7.55 (d, 2H, J=7.4 Hz); 7.45 (d, 2H, J=8.4 Hz); 7.39
(t, 5H, J=7.6 Hz); 7.30 (d, 2H, J=8 Hz); 7.17 (d, 2H, J=8.4 Hz);
7.11 (d, 2H, J=8.4 Hz); 5.77 (d, 1H, J=5.6 Hz); 5.50 (s, 1H); 5.26
(s, 1H); 4.67-4.63 (m, 2H); 4.25-4.22 (m, 2H); 4.06 (t, 1H, J=8
Hz); 3.95 (q, 1H, J=6.8, 10.4 Hz); 3.67-3.48 (m, 2H); 3.18-2.99 (m,
2H).
EXAMPLE 9
##STR00042##
[0171] EXAMPLE 10
##STR00043## ##STR00044##
[0172] EXAMPLE 11
##STR00045##
[0173] EXAMPLE 12
##STR00046##
[0174] EXAMPLE 13
##STR00047##
[0175] EXAMPLE 14
##STR00048##
[0176] EXAMPLE 15
##STR00049##
[0177] EXAMPLE 16
##STR00050##
[0178] EXAMPLE 17
##STR00051##
[0179] EXAMPLE 18
##STR00052##
TABLE-US-00003 [0180] Exemplary yield and crude product purity
Purity of crude cpds Compound (%, by ELSD) yield (%) 86 96 33 87 92
33 88 84 31 89 98 31 90 97 27 91 96 46 92 92 35 93 87 28 94 86 34
95 98 40 96 85 33 97 95 35 98 94 45 99 97 39 100 98 39 101 96 40
102 98 47 103 63 23 104 90 38 105 96 31 106 95 49 107 98 46 108 41
18 109 89 38 110 89 41 111 81 18 112 20 12 113 15 8 114 35 12 115
95 22 116 84 42 117 97 39 118 88 34 119 77 25 120 92 44 Ra =
adenosine
Analysis of Some Typical Example Compounds
##STR00053##
[0182] proton (400 MHz, d.sup.6-DMSO): 8.29 (s, 1H, H-8), 8.11 (s,
1H, H-2), 8.00 (d, 1H, J=1.5 Hz, Ar--H), 7.87 (broad s, 1H, NH),
7.61 (dd, 1H, J=1.5, 8.6 Hz, Ar--H), 7.41 (d, 1H, J=8.6 Hz, ArH),
7.30 (broad s, 2H, NH), 7.21 (broad s, 1H, NH), 5.86 (d, 1H, J=5.1
Hz, H'-1), 5.61 (d, 1H, J=6.0 Hz, OH), 5.45 (d, 1H, J=5.4 Hz, OH),
4.72 (qua, 1H, J=5.2 Hz, H'-2 or H'-3), 4.54 (dd, J=15.2, 4.7 Hz,
H'-5), 4.47 (dd, 1H, J=15.2, 7.4 Hz, H'-5), 4.31 (qua, 1H, J=4.7
Hz, H'-3 or H'-2), 4.29 (dt, 1H, J=4.7, 7.4 Hz).
[0183] carbon (100 MHz, d.sup.6-DMSO): 168.7, 156.6, 154.8, 153.2,
149.8, 142.9, 140.4, 139.3, 128.4, 121.9, 119.8, 117.6, 109.8,
88.5, 82.7, 73.5, 71.8, 46.9.
##STR00054##
[0184] proton (400 MHz, d.sup.6-DMSO): 8.38 (s, 1H, H-8), 8.15 (s,
1H, H-2), 7.95 (broad s, 1H, NH), 7.64 (d, 1H, J=1.5 Hz, Ar--H),
7.54 (dd, 1H, J=1.5, 8.3 Hz, Ar--H), 7.31 (d, 1H, J=8.5 Hz, Ar--H),
7.30 (broad s, 1H, NH), 7.25 (broad s, 1H, NH), 5.85 (d, 1H, J=6.3
Hz, H'-1), 5.54 (d, 1H, J=6.2 Hz, OH), 5.38 (d, 1H, J=5.1 Hz, OH),
4.82 (qua, 1H, J=5.8 Hz, H'-3 or H'-2), 4.70 (dd, 1H, J=4.6, 13.8
Hz, H'-5), 4.49-4.38 (m, 2H, H'-5+H'4), 4.35 (m, 1H, H'), 2.10 (s,
3H, CH.sub.3).
[0185] carbon (100 MHz, d.sup.6-DMSO): 170.2, 167.9, 156.6, 153.2,
150.0, 140.4, 135.9, 131.1, 129.6, 122.3, 119.8, 110.0, 109.7,
87.8, 82.4, 73.2, 71.9, 46.9, 31.5.
##STR00055##
[0186] proton (400 MHz, d.sup.6-DMSO): 8.30 (s, 1H, H-8), 8.11 (s,
1H, H-1), 8.08 (d, 1H, J=1.5 Hz, Ar--H), 7.59 (broad s, 1H, NH),
7.63 (dd, 1H, J=1.5, 8.3 Hz, Ar--H), 7.43 (d, 1H, J=8.3 Hz, Ar--H),
7.31 (broad s, 2H, NH.sub.2), 7.22 (broad s, 1H, NH), 5.87 (d, 1H,
J=5.0 Hz, H'-1), 5.63 (d, 1H, J=5.8 Hz, OH), 5.46 (d, 1H, J=5.4 Hz,
OH), 4.75 (qua, 1H, J=5.0 Hz, H'-2 or H'-3), 4.54 (dd, 1H, J=4.7,
15.3 Hz, H'-5), 4.48 (dd, 1H, J=7.6, 15.3 Hz, H'-5), 4.34 (qua, 1H,
J=4.7 Hz, H'-2 or H'-3), 4.25 (dt, 1H, J=4.7, 7.4 Hz, H'-4), 3.24
(qua, 2H, J=7.3 Hz, CH.sub.2), 1.32 (t, 3H, J=7.3 Hz,
CH.sub.3).
[0187] carbon (10 MHz, d.sup.6-DMSO): 168.7, 156.6, 153.8, 153.2,
149.8, 143.0, 140.4, 139.1, 128.4, 121.9, 119.8, 117.6, 109.9,
88.5, 82.7, 73.4, 71.8, 46.9, 27.2, 15.6.
TABLE-US-00004 Yield and purity of crude products Ra = ##STR00056##
Purity of Crude cpds (%, by Compound# R.sup.1 ELSD) yield (%) 121
Ph 96.9 38 122 Ph 94.8 5 123 Ph 96.7 31 124 Ph 97.8 34 125 Ph 50.6
38 126 Ph 97.3 21 127 Ph 98.3 41 128 Ph 97.7 26 129 Ph 97.7 14 130
Ph 96.7 28 131 Ph 91.1 23 132 Ph 97.9 39 133 Ph 96.9 36 134 Ph 89.0
31 135 Ph 97.5 33 136 Ph 96.4 22 137 Ph 97.0 30 138 Ph 96.7 28 139
Ph 84.6 23 140 Ph 83.3 24 141 Ph 97.1 28 142 Ph 97.0 27 143 Ph 95.3
35 144 Ph 72.8 25 145 Ph 88.6 30 146 Ph 85.7 8 147 Ph 66.3 23 148
Ph 68.1 25 149 Ph 26.1 15 150 Ph 97.7 7 151 Ph 99.1 5 152 Ph 97.8 6
153 Ph 48.4 17 154 Ph 95.6 26 155 Ph 96.0 31 156 Ph 74.50 2 157 Ph
7.9 3 158 Ph 53.6 17 159 Pr 96.4 12 160 Pr 98.2 37 161 Pr 96.8 20
162 Pr 96.9 36 163 Pr 97.4 19 164 Pr 96.4 36 165 Pr 96.7 27 166 Pr
97.2 24 167 Pr 96.8 17 168 Pr 95.0 33 169 Pr 82.1 15 170 Pr 95.8 34
171 Pr 97.0 37 172 Pr 97.4 23 173 Pr 96.8 33 174 Pr 96.9 37 175 Pr
96.9 41 176 Pr 96.9 28 177 Pr 89.9 7 178 Pr 98.2 35 179 Pr 97.3 37
180 Pr 96.4 36 181 Pr 93.7 28 182 Pr 80.7 26 183 Pr 96.6 36 184 Pr
97.7 36 185 Pr 60.2 21 186 Pr 86.9 33 187 Pr 39.7 15 188 Pr 97.2 2
189 Pr 99.5 60 190 Pr 98.4 4 191 Pr 60.0 5 192 Pr 96.0 34 193 Pr
96.7 36 194 Pr 95.4 12 195 Pr 17.0 2 196 Pr 80.5 11
Analysis of a Typical Example Compounds
##STR00057##
[0189] proton (400 MHz, d.sup.6-DMSO): 8.13 (d, 1H, J=1.3 Hz,
Ar--H), 8.09 (d, 1H, J=8.7 Hz, Ar--H), 7.93 (broad s, 1H, NH), 7.86
(broad s, 1H, NH), 7.70 (dd, 1H, J 1.3, 8.4 Hz, Ar--H), 7.64 (d,
1H, J=8.7 Hz, Ar--H), 7.50-7.30 (m, 5H, Ar--H), 7.28 (d, 1H, J=8.5
Hz, Ar--H), 7.25 (broad s, 1H, NH), 5.75 (d, 1H, J=5.48 Hz, OH),
5.53 (d, 1H, J=6.4 Hz, OH), 5.37 (d, 1H, J=1.7 Hz, H'-1), 4.75-4.60
(m, 3H, CH+CH.sub.2), 4.54-4.40 (m, 2H, CH), 4.30-4.23 (m, 2H,
CH).
[0190] Carbon (100 MHZ, d.sup.6-DMSO): 167.6, 161.1, 152.2, 146.2
145.3, 141.8, 138.9, 138.2, 138.1, 129.9, 129.7, 129.4, 127.8,
127.7, 125.0, 123.2, 121.3, 116.9, 108.8, 89.7, 82.3, 74., 71.8,
46.3, 34.7.
EXAMPLE 19
##STR00058##
TABLE-US-00005 ##STR00059## [0191] Retention time, observed mass,
yield Compound 2 components 19-III and 19-IV 312 Rt = 4.24 min (M +
H).sup.+= 516 (26%), Rt = 4.75 min (M + H).sup.+= 544 (72%) 313 Rt
= 4.80 min (M + H).sup.+= 550 (3%), Rt = 5.28 min (M + H).sup.+=
578 (72%) 314 Rt = 4.52 min (M + H).sup.+= 546 (23%), Rt = 4.96 min
(M + H).sup.+= 574 (74%) 315 Rt = 4.70 min (M + H).sup.+= 530
(11%), Rt = 5.17 min (M + H).sup.+= 558 (88%) 316 Rt = 4.69 min (M
+ H).sup.+= (2%), Rt = 5.23 min (M + H).sup.+= (19%) 317 Rt = 5.82
min (M + H).sup.+= 572 (22%), Rt = 6.26 min (M + H).sup.+= 544
(78%) 318 Rt = 4.81 min (M + H).sup.+= 596 (73%), Rt = 5.40 min (M
+ H).sup.+= 624 (27%) 319 Rt = 4.68 min (M + H).sup.+= 530 (2%), Rt
= 5.15 min (M + H).sup.+= 558 (98%) 320 Rt = 5.92 min (M +
H).sup.+= 608 (25%), Rt = 6.37 min (M + H).sup.+= 636 (75%) 321 Rt
= 5.97 min (M + H).sup.+= 622 (52%), Rt = 6.48 min (M + H).sup.+=
650 (48%) 322 Rt = 5.74 min (M + H).sup.+= 592 (43%), Rt = 6.27 min
(M + H).sup.+= 620 (57%) 323 Rt = 5.15 min (M + H).sup.+= 569
(14%), Rt = 5.98 min (M + H).sup.+= 597 (86%) 324 Rt = 5.63 min (M
+ H).sup.+= 603 (46%), Rt = 6.62 min (M + H).sup.+= 631 (52%) 325
Rt = 5.34 min (M + H).sup.+= 599 (23%), Rt = 6.20 min (M +
H).sup.+= 627 (77%) 326 Rt = 5.51 min (M + H).sup.+= 583 (38%), Rt
= 6.38 min (M + H).sup.+= 611 (62%) 327 Rt = 5.58 min (M +
H).sup.+= 603 (90%), Rt = 6.46 min (M + H).sup.+= 631 (8%) 328 Rt =
6.54 min (M + H).sup.+= 625 (55%), Rt = 7.41 min (M + H).sup.+= 653
(45%) 329 Rt = 5.77 min (M + H).sup.+= 647 (31%), Rt = 6.66 min (M
+ H).sup.+= 677 (55%) 330 Rt = 5.59 min (M + H).sup.+= 612 (28%),
Rt = 6.20 min (M + H).sup.+= 640 (61%) 331 Rt = 5.51 min (M +
H).sup.+= 583 (22%), Rt = 6.31 min (M + H).sup.+= 611 (78%) 332 Rt
= 6.57 min (M + H).sup.+= 661 (42%), Rt = 7.50 min (M + H).sup.+=
689 (58%) 333 Rt = 6.75 min (M + H).sup.+= 675 (38%), Rt = 7.62 min
(M + H).sup.+= 703 (60%) 334 Rt = 6.56 min (M + H).sup.+= 645
(55%), Rt = 7.38 min (M + H).sup.+= 673 (44%) 335 Rt = 5.03 min (M
+ H).sup.+= 535 (17%), Rt = 5.77 min (M + H).sup.+= 563 (82%) 335
Rt = 5.58 min (M + H).sup.+= 569 (11%), Rt = 6.35 min (M +
H).sup.+= 597 (87%) 336 Rt = 5.26 min (M + H).sup.+= 565 (15%), Rt
= 6.0 min (M + H).sup.+= 593 (84%) 337 Rt = 5.33 min (M + H).sup.+=
5.49 (12%), Rt = 6.04 min (M + H).sup.+= 577 (88%) 338 Rt = 5.41
min (M + H).sup.+= 569 (79%), Rt = 6.27 min (M + H).sup.+= 597 (5%)
339 Rt = 6.44 min (M + H).sup.+= 591 (36%), Rt = 7.29 min (M +
H).sup.+= 619 (64%) 340 Rt = 5.67 min (M + H).sup.+= 615 (18%), Rt
= 6.46 min (M + H).sup.+= 643 (79%) 341 Rt = 6.51 min (M +
H).sup.+= 591 (8%) 342 Rt = 5.37 min (M + H).sup.+= 549 (25%), Rt =
6.20 min (M + H).sup.+= 577 (75%) 343 Rt = 6.54 min (M + H).sup.+=
627 (19%), Rt = 7.40 min (M + H).sup.+= 655 (81%) 344 Rt = 6.64 min
(M + H).sup.+= 641 (30%), Rt = 7.52 min (M + H).sup.+= 669 (69%)
345 Rt = 6.41 min (M + H).sup.+= 611 (58%), Rt = 7.26 min (M +
H).sup.+= 639 (42%)
EXAMPLE 20
##STR00060##
[0192] Analysis of Some Typical Example Compounds:
##STR00061##
[0194] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.37 (s, 1H);
8.24 (s, 1H); 7.57 (d, 2H, J=8.8 Hz); 7.35 (d, 2H, J=7.2 Hz); 7.30
(t, 2H, J=7.6 Hz); 7.21 (t, 2H, J=7.2 Hz), 6.77 (d, 2H, J=8.8 Hz),
5.81 (d, 1H, J=4.4 Hz); 4.71-4.63 (m, 3H), 4.64 (t, 1H, J=4.8 Hz);
4.46-4.38 (m, 2H); 4.33-4.30 (m, 1H), 3.76 (s, 3H).
##STR00062##
Beta Isomer:
[0195] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.27 (s, 1H),
7.88 (s, 1H), 7.55-7.41 (m, 6H); 7.28 (dd, 2H, J=1.2, 7.6 Hz); 6.84
(d, 2H, J=8.8 Hz); 5.31 (d, 1H, J=2 Hz); 4.66 (d, 1H, J=11.2 Hz);
4.51 (s, 1H); 4.41-4.32 (m, 3H); 3.97-3.88 (m, 3H); 2.98 (s, 3H);
1.73-1.66 (m, 2H); 1.39-1.26 (m, 12H); 0.87-0.84 (m, 3H).
Alpha Isomer:
[0196] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.25 (s, 1H),
7.82 (d, 3H, J=8.4 Hz); 7.51-7.46 (m, 6H); 7.11 (d, 2H, J=8.8 Hz);
5.43 (d, 1H, J=4.4 Hz); 4.91 (s, 1H); 4.37 (s, 1H); 4.23 (q, 1H,
J=5.6, 8.8 Hz); 4.06 (t, 2H, J=6.4 Hz); 3.79 (s, 3H); 1.77-1.70 (m,
2H); 1.44-1.26 (m, 12H); 0.87-0.84 (m, 3H).
EXAMPLE 21
##STR00063##
[0197] Analysis of Some Typical Example Compounds:
##STR00064##
[0199] proton (400 MHz, d.sup.6-DMSO): 8.36 (s, 1H, H-8), 8.25 (s,
1H, H-2), 7.88 (s, 2H, ArCH), 7.62 (d, 2H, J=8.8 Hz, ArCH), 6.84
(d, 2H, J=8.8 Hz, ArCH), 5.85 (d, 1H, J=3.6 Hz, H'-1), 4.73 (dd,
1H, J=3.5, 15.8 Hz, CH), 4.57-4.64 (m, 2H, CH.sub.2), 4.36 (t, 1H,
J=5.6 Hz, CH), 4.22 (m, 1H, H'-4), 3.80 (s, 3H, OCH.sub.3).
EXAMPLE 22
##STR00065##
[0200] Analysis of Some Typical Example Compounds:
##STR00066##
[0201] Isomer 1:
[0202] proton NMR (400 MHz, d.sub.8-DMSO): .delta.: 8.48 (s, 1H);
8.17 (s, 1H); 7.39-7.22 (m, 6H); 7.11 (d, 2H, J=7.6 Hz); 6.86 (d,
2H, J=6.8 Hz); 5.93 (d, 1H, J=4.8 Hz); 4.67 (t, 1H, J=4.8 Hz); 4.59
(t, 1H J=3.6 Hz); 4.34 (t, 1H, J=5.2 Hz); 4.22 (q, 1H, J=4.8, 10
Hz); 4.00 (dd, 1H, J=6.8, 15.2 Hz); 3.76 (dd, 1H, J=7.6, 14.8 Hz);
3.26 (dd, 1H, J=4.4, 14 Hz); 3.05 (dd, 1H, J=3.6, 14.4 Hz).
Isomer 2:
[0203] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.59 (s, 1H);
8.31 (s, 1H); 7.38-7.23 (m, 5H); 7.11-7.06 (m, 3H); 6.88 (d, 2H,
J=6.8 Hz); 5.97 (d, 1H, J=6 Hz); 4.84 (t, 1H, J=4.8 Hz); 4.50 (t,
1H, J=3.6 Hz); 4.25-4.22 (m, 2H); 4.14 (dd, 1H, J=3.6, 14.8 Hz);
3.23 (dd, 1H, J=5.2, 14.4 Hz); 3.00 (dd, 1H, J=2.8, 14 Hz).
##STR00067##
Isomer 1:
[0204] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 10.94 (s, 1H);
8.59 (s, 1H); 8.26 (s, 1H); 7.48 (d, 1H, J=8 Hz); 7.32-7.26 (m,
4H); 7.10 (s, 1H); 7.06 (t, 1H, J=7.6 Hz); 6.93 (t, 1H, J=7.6 Hz);
6.69-6.67 (m, 2H); 5.95 (d, 1H, J=5.2 Hz); 4.66 (t, 1H, J=5.6 Hz);
4.54 (t, 1H, J=3.2 Hz); 4.33 (t, 1H J=4.8 Hz); 4.25 (q, 1H, J=5.2,
10.8 Hz); 4.00 (dd, 1H, J=6.4, 15.2 Hz); 3.76 (dd, 1H, J=4, 14.8
Hz); 3.37-3.25 (m, 2H).
Isomer 2:
[0205] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 10.95 (s, 1H);
8.68 (s, 1H); 7.43 (d, 1H, J=8 Hz); 7.32 (d, 2H, J=8 Hz); 7.27-7.25
(m, 2H); 7.09 (s, 1H); 7.06 (t, 1H J=8 Hz); 6.92 (t, 1H, J=8 Hz);
6.70 (dd, 2H, J=3.6, 7.6 Hz); 5.99 (d, 1H, J=5.6 Hz); 4.81 (t, 1H,
J=5.2 Hz); 4.47 (t, 1H, J=3.2 Hz); 4.29-4.22 (m, 2H); 4.12 (dd, 1H,
J=4.4, 14.8 Hz); 3.68 (dd, 1H, J=8.4, 14.8 Hz); 3.36 (dd, 1H,
J=5.2, 15.2 Hz); 3.24 (dd, 1H, J=2.4, 15.2 Hz).
##STR00068##
Isomer 1:
[0206] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.96 (s, 1H);
8.49 (s, 1H); 8.03 (s, 1H); 7.73 (d, 2H, J=10.8 Hz); 7.67 (d, 2H,
J=7.2 Hz); 7.49 (t, 2H, J=7.6 Hz); 7.40-7.35 (m, 2H); 7.34 (d, 2H,
J=8.4 Hz); 5.95 (d, 1H, J=5.6 Hz); 4.70 (t, 1H, J=5.2 Hz); 4.65 (t,
1H, J=4.4 Hz); 4.31 (t, 1H, J=4.8 Hz); 4.27-4.23 (m, 1H); 3.95 (dd,
1H, J=7.6, 15.2 Hz); 3.77 (dd, 1H, J=4, 14.8 Hz); 3.26-3.24 (m,
2H).
Isomer 2:
[0207] proton NMR (400 MHz, d.sub.6-DMSO): .delta.: 8.97 (s, 1H);
8.51 (s, 1H); 7.82 (s, 1H); 7.73 (d, 2H, J=8.8 Hz); 7.67 (d, 2H,
J=7.2 Hz); 7.49 (t, 2H, J=7.2 Hz); 7.40-7.35 (m, 2H); 7.25 (d, 2H,
J=8.4 Hz); 5.95 (d, 1H, J=5.6 Hz); 4.79 (t, 1H, J=4.8 Hz); 4.62 (t,
1H, J=5.6 Hz); 4.27-4.22 (m, 2H); 4.16 (dd, 1H, J=4, 14.8 Hz);
3.33-3.21 (m, 2H).
EXAMPLE 23
##STR00069##
##STR00070##
##STR00071##
[0208] General Method 3-a.
Analysis of a Typical Example Compounds:
##STR00072##
[0210] proton (400 MHz: d.sub.6 DMSO) 3.79 (s, 3H, OCH.sub.3), 4.30
(bs, 2H, H2, H3), 4.43 (bd, J 6.0 Hz, 3H, H4, NCH.sub.2Ph), 4.65
(dd, J 15.6, 6.2 Hz, 1H, H5a), 4.91 (d, J 14.8 Hz, 1H, H5b), 5.35
(s, 1H, H1), 6.64 (d, J 8.8 Hz, 2H, ArH), 6.98 (d, J 8.8.degree.
Hz, 2H, ArH), 7.19 (d, J 8.8 Hz, 2H, ArH), 7.22-7.36 (m, 5H, ArH,
NHa), 7.42-7.56 (m, 5H, ArH), 7.71 (t, J 7.6 Hz, 2H, ArH), 7.82
(bs, 1H, NHb).
##STR00073##
[0211] proton (400 MHz: d.sub.6 DMSO) 4.24-4.31 (m, 1H, H4), 4.38
(dd, J 7.4, 5.0 Hz, 1H, H3), 4.47 (dd, J4.4, 1.6 Hz, 1H, H2), 4.50
(dd, J 15.6, 7.6 Hz, 1H, H5a), 4.76 (dd, J 15.6, 2.8 Hz, 1H, H5b),
5.33 (d, J 1.2 Hz, 1H, H1), 7.29 (dd, J 7.8, 1.4 Hz, 2H, ArH),
7.40-7.62 (m, 8H, ArH, ArCONHa), 7.68 (d, J 8.4 Hz, 2H, ArH), 7.83
(s, 1H, ArCONHb), 7.88 (d, J 8.8 Hz, 2H, ArH), 7.91-7.99 (m, 3H,
ArH), 10.46 (s, 1H, ArNHCOPh).
EXAMPLE 24
##STR00074##
[0212] Analysis of Some Typical Example Compounds:
##STR00075##
[0214] proton (d.sup.6-DMSO, 400 MHz): 8.51 (s, 1H, H-2/8), 8.31
(s, 1H, H-2/8), 7.60-7.05 (m, 8H, ArCH), 5.86 (d, 1H, J=5.6, Hz,
H'-1), 4.67 (t, 1H, J=5.5 Hz, H'-2/3), 4.64 (d, 1H, J.sub.AB=16.1
Hz, HA-), 4.39 (d, 1H, J.sub.AB=16.1 Hz, HB-), 4.34 (t, 1H, J=5.1
Hz, H-2/3), 4.09 (t, 1H, J=4.2 Hz,), 3.99 (m, 1H, H'4), 3.67 (dd,
1H, J=5.8 Hz, 14.0 Hz, HA), 3.58 (dd, 1H, J=7.6, 14.0 Hz, HB), 3.14
(dd, 1H, J=5.1, 14.4 Hz, H'-5A), 3.02 (dd, 1H, J=4.6, 14.4 Hz,
H'-5B).
##STR00076##
[0215] proton (d.sup.6-DMSO, 400 MHz): 8.48 (s, 1H, H-2/8), 8.29
(s, 1H, H-2/8), 7.57-7.00 (m, 8H, ArCH), 5.88 (d, 1H, J=5.8 Hz,
H'-1), 4.68 (t, J=5.2 Hz, H'--), 4.60 (d, 1H, J.sub.AB=16.1 Hz,
H--), 4.38 (d, 1H, J.sub.AB=16.1 Hz, H), 4.34 (t, 1H, J=5.1 Hz,
H-), 4.07 (t, 1H, J=4.6 Hz, H), 4.01 (m, 1H, H'-4), 3.64 (d, 2H, AB
system, H--), 3.12 (dd, 1H, J-5.2, 14.6 Hz, H.sub.A--), 3.01 (dd,
1H, J=4.4, 14.6 Hz, H.sub.B--).
Exemplary Compounds of the Invention:
[0216] The substructures A-H listed below are substituents in the
field R1 in the libraries of compounds that follow.
##STR00077##
[0217] Others substituents referred to in the following libraries
may be subsequently found in the text at the end of examples.
EXAMPLE 25
TABLE-US-00006 ##STR00078## [0218] R (on Comp. R1 R2 ISOMER arm) 1
A IIa-1 L and D H 2 A IIb-1 L and D H 3 A IIc-1 L and D H 4 A IId-1
L and D H 5 A IIe-1 L H 6 A IIe-1 D H 7 A IIf-1 L and D H 8 A IIg-1
L and D H 9 A IIh-1 L and D H 10 A IIi-1 L and D H 11 A IIj-1 L and
D H 12 A IIk-1 L and D H 13 A IIl-1 L and D H 14 A IIo-1 L H 15 A
IIo-1 D H 16 B IIa-1 L and D methyl 17 B IIb-1 L and D methyl 18 B
IIc-1 L and D methyl 19 B IId-1 L and D methyl 20 B IIe-1 L and D H
21 B IIf-1 L and D H 22 B IIh-1 L and D methyl 23 B IIi-1 L and D
ethyl 24 B IIj-1 L and D ethyl 25 B IIk-1 L and D methyl 26 B IIr-1
L and D methyl 27 B IIl-1 L and D methyl 28 B IIo-1 L and D methyl
29 B IIp-1 L and D methyl 30 B IIq-1 L and D methyl
EXAMPLE 26
TABLE-US-00007 ##STR00079## [0219] R (on Comp. R1 R2 Isomer arm) 31
C IIa-1 L and D H 32 C IIb-1 L and D H 33 D IIb-1 L and D H 34 C
IIc-1 L and D H 35 C IId-1 L and D H 36 D IId-1 L and D H 37 D
IIe-1 L and D H 38 C IIe-1 L and D H 39 D IIf-1 L and D H 40 C
IIf-1 L and D H 41 D IIg-1 L and D H 42 C IIh-1 L and D H 43 D
IIh-1 L and D H 44 C IIi-1 L H 45 D IIi-1 L H 46 C IIj-1 L H 47 D
IIj-1 L H 48 C IIk-1 L and D H 49 D IIk-1 L and D H 50 C IIr-1 L H
51 D IIr-1 L H 52 C IIl-1 L H 53 D IIl-1 L H 54 C IIn-1 L H 55 D
IIn-1 L H 56 C IIo-1 L H 57 D IIo-1 L H 58 C IIp-1 L H 59 D IIp-1 L
H 60 C IIq-1 L H 61 D IIq-1 L H 62 C IIb-1 L H 63 D IIb-1 L H 64 C
IIe-1 L H 65 D IIe-1 L H ##STR00080## IIa-1 ##STR00081## IIb-1
##STR00082## IIc-1 ##STR00083## IId-1 ##STR00084## IIe-1
##STR00085## IIf-1 ##STR00086## IIg-1 ##STR00087## IIh-1
##STR00088## IIi-1 ##STR00089## IIj-1 ##STR00090## IIk-1
##STR00091## IIl-1 ##STR00092## IIm-1 ##STR00093## IIn-1
##STR00094## IIo-1 ##STR00095## IIp-1 ##STR00096## IIq-1
##STR00097## IIr-1
EXAMPLE 27
TABLE-US-00008 ##STR00098## [0220] Comp. R1 R2 R3 R4 66 A .alpha.4
.nu.2 .SIGMA.1 67 A .beta.7 .nu.2 .SIGMA.1 68 A .beta.6 .nu.2
.SIGMA.1 69 A .chi.5 .nu.2 .SIGMA.1 70 A .kappa.4 .nu.2 .SIGMA.1 71
A .alpha.4 .nu.2 .alpha.4 72 A .beta.7 .nu.2 .alpha.4 73 A .beta.6
.nu.2 .alpha.4 74 A .chi.5 .nu.2 .alpha.4 75 A .kappa.4 .nu.2
.alpha.4 76 A .alpha.4 .alpha.1 .SIGMA.1 77 A .beta.7 .alpha.1
.SIGMA.1 78 A .beta.6 .alpha.1 .SIGMA.1 79 A .chi.5 .alpha.1
.SIGMA.1 80 A .kappa.4 .alpha.1 .SIGMA.1 81 A .alpha.4 .alpha.1
.SIGMA.1 82 A .beta.7 .alpha.1 .alpha.4 83 A .beta.6 .alpha.1
.alpha.4 84 A .chi.5 .alpha.1 .alpha.4 85 A .kappa.4 .alpha.1
.alpha.4
EXAMPLE 28
TABLE-US-00009 ##STR00099## [0221] Comp. R1 R2 86 A .beta.1 87 A
.gamma.1 88 A .beta.2 89 A .delta.2 90 A .epsilon.1 91 A .kappa.1
92 A .pi.1 93 A .omega.1 94 A .epsilon.2 95 A .sigma.1 96 A .beta.3
97 A .gamma.2 98 A .gamma.3 99 A .delta.2 100 A .epsilon.3 101 A
.kappa.2 102 A .pi.2 103 A .epsilon.4 104 A .beta.4 105 A .gamma.4
106 A .beta.5 107 A .phi.1 108 A .pi.3 109 A .phi.2 110 A .nu.1 111
A .nu.2 112 A .nu.3 113 A .nu.4 114 A .lamda.1 115 A .nu.5 116 A
.nu.6 117 A .epsilon.5 118 A .epsilon.6 119 A .nu.7 120 A
.chi.1
EXAMPLE 29
TABLE-US-00010 ##STR00100## [0222] Comp. R1 R2 121 C .alpha.1 122 C
.beta.1 123 C .gamma.1 124 C .beta.2 125 C .delta.1 126 C
.epsilon.1 127 C .kappa.1 128 C .pi.1 129 C .omega.1 130 C
.epsilon.2 131 C .sigma.1 132 C .beta.3 133 C .gamma.2 134 C
.gamma.3 135 C .delta.2 137 C .epsilon.2 137 C .kappa.3 138 C .pi.2
139 C .epsilon.4 140 C .beta.4 141 C .gamma.4 142 C .beta.5 143 C
.phi.1 144 C .pi.3 145 C .phi.2 146 C .nu.1 147 C .nu.2 148 C .nu.3
149 C .nu.4 150 C .lamda.1 151 C .nu.5 152 C .nu.6 153 C .rho.1 154
C .epsilon.5 155 C .epsilon.6 156 C .rho.2 157 C .nu.7 158 C .chi.1
159 D .alpha.1 160 D .beta.1 161 D .gamma.1 162 D .beta.2 163 D
.delta.1 164 D .epsilon.1 165 D .kappa.1 166 D .pi.1 167 D .omega.1
168 D .epsilon.2 169 D .sigma.1 170 D .beta.3 171 D .gamma.2 172 D
.gamma.3 173 D .delta.2 174 D .epsilon.3 175 D .kappa.2 176 D .pi.2
177 D .epsilon.4 178 D .beta.4 179 D .gamma.4 180 D .beta.5 181 D
.phi.1 182 D .pi.3 183 D .phi.2 184 D .nu.1 185 D .nu.2 186 D .nu.3
187 D .nu.4 188 D .lamda.1 189 D .nu.5 190 D .nu.6 191 D .rho.1 192
D .epsilon.5 193 D .epsilon.6 194 D .rho.2 195 D .nu.7 196 D
.chi.1
EXAMPLE 30
TABLE-US-00011 ##STR00101## [0223] Comp. R1 R2 R3 197 A .pi.4
.psi.1 198 A .beta.1 .psi.1 199 A .xi.1 .psi.1 200 A .epsilon.5
.psi.1 201 A .epsilon.2 .psi.1 202 A .sigma.1 .psi.1 203 A .alpha.2
.psi.1 204 A .mu.1 .psi.1 205 A .tau.1 .psi.1 206 A .tau.2 .psi.1
207 A .mu.2 .psi.1 208 A .epsilon.7 .psi.1 209 A .mu.3 .psi.1 210 A
.gamma.2 .psi.1 211 A .gamma.5 .psi.1 212 A .pi.4 .alpha.1 213 A
.beta.1 .alpha.1 214 A .xi.1 .alpha.1 215 A .epsilon.5 .alpha.1 216
A .epsilon.2 .alpha.1 217 A .sigma.1 .alpha.1 218 A .alpha.2
.alpha.1 219 A .mu.1 .alpha.1 220 A .tau.1 .alpha.1 221 A .tau.2
.alpha.1 222 A .epsilon.7 .alpha.1 223 A .mu.3 .alpha.1 224 A
.gamma.2 .alpha.1 225 A .gamma.5 .alpha.1 226 C .pi.4 .psi.1 227 C
.beta.1 .psi.1 228 C .xi.1 .psi.1 229 C .epsilon.5 .psi.1 230 C
.mu.1 .psi.1 231 C .tau.1 .psi.1 232 C .tau.2 .psi.1 233 C .mu.2
.psi.1 234 C .epsilon.7 .psi.1 235 C .mu.3 .psi.1 236 C .gamma.2
.psi.1 237 C .gamma.5 .psi.1 238 C .xi.1 .alpha.1 239 C .epsilon.5
.alpha.1 240 C .epsilon.2 .alpha.1 241 C .sigma.1 .alpha.1 242 C
.alpha.2 .alpha.1 243 C .mu.1 .alpha.1 244 C .tau.1 .alpha.1 245 C
.tau.2 .alpha.1 246 C .mu.2 .alpha.1 247 C .epsilon.7 .alpha.1 248
C .mu.3 .alpha.1 249 C .gamma.2 .alpha.1 250 C .gamma.5 .alpha.1
251 D .pi.4 .alpha.1 252 D .beta.1 .alpha.1 253 D .epsilon.2 .psi.1
254 D .sigma.1 .psi.1
EXAMPLE 31
TABLE-US-00012 ##STR00102## [0224] Comp. R1 R2 255 A .sigma.2 256 A
.xi.3 257 A .beta.6 258 A .theta.1 259 A .epsilon.8 260 A .chi.2
261 A .chi.3 262 A .chi.4 263 A .nu.8 264 A .beta.8 265 A .pi.5 266
A .mu.4 267 A .mu.5 268 A .tau.3 269 A .alpha.3 270 A .tau.4 271 A
.sigma.3 272 A .beta.9 273 A .mu.6 274 C .xi.2 275 C .beta.6 276 C
.psi.1 277 C .theta.1 278 C .chi.2 219 C .chi.3 280 C .chi.4 281 C
.nu.8 282 C .beta.8 283 C .pi.5 284 C .mu.4 285 C .mu.5 286 C
.tau.3 287 C .alpha.3 288 C .tau.4 289 C .sigma.3 290 C .beta.9 291
C .mu.6 292 D .sigma.2 293 D .xi.2 294 D .beta.6 295 D .phi.1 296 D
.theta.1 297 D .epsilon.8 298 D .chi.2 299 D .chi.3 300 D .chi.4
301 D .nu.8 302 D .beta.8 303 D .pi.5 304 D .mu.4 305 D .mu.5 306 D
.tau.3 307 D .alpha.3 308 D .tau.3 309 D .psi.3 310 D .beta.9 311 D
.mu.6
EXAMPLE 32
TABLE-US-00013 ##STR00103## [0225] Comp. R1 R2 R3 312 A .SIGMA.2
.alpha.4 313 A .SIGMA.2 .beta.6 314 A .SIGMA.2 .chi.5 315 A
.SIGMA.2 .epsilon.9 316 A .SIGMA.2 .beta.7 317 A .SIGMA.2
.epsilon.10 318 A .psi.1 .theta.2 319 A .SIGMA.2 .epsilon.11 320 A
.SIGMA.2 .chi.6 321 A .psi.1 .chi.4 322 A .SIGMA.2 .sigma.3 323 C
.SIGMA.2 .alpha.4 324 C .SIGMA.2 .beta.6 325 C .SIGMA.2 .chi.5 326
C .SIGMA.2 .epsilon.9 327 C .psi.1 .beta.7 328 C .psi.1 .epsilon.10
329 C .SIGMA.2 .theta.2 330 C .SIGMA.2 .xi.3 331 C .SIGMA.2
.epsilon.11 332 C .SIGMA.2 .chi.6 333 C .SIGMA.2 .chi.4 334 C
.psi.1 .sigma.3 335 D .SIGMA.2 .alpha.4 336 D .SIGMA.2 .beta.6 337
D .SIGMA.2 .chi.5 338 D .SIGMA.2 .epsilon.9 339 D .psi.1 .beta.7
340 D .SIGMA.2 .epsilon.10 341 D .SIGMA.2 .theta.2 342 D .SIGMA.2
.epsilon.11 343 D .SIGMA.2 .chi.6 344 D .SIGMA.2 .chi.4 345 D
.psi.1 .sigma.3
EXAMPLE 33
TABLE-US-00014 ##STR00104## [0226] Comp. R1 R2 346 A .chi.5 347 D
.chi.5 348 A .epsilon.9 349 D .epsilon.9 350 A .chi.6 351 D .chi.7
352 A .alpha.1 353 C .alpha.1 354 D .alpha.1 355 A .theta.3 356 C
.theta.3 357 D .theta.3 358 A .gamma.3 359 C .gamma.3 360 D
.gamma.3 361 A .theta.4 362 C .theta.4 363 D .theta.4 364 A
.gamma.1 365 C .gamma.1 366 D .gamma.1 367 A .epsilon.3 368 C
.epsilon.3 369 D .epsilon.3 370 A .chi.1 371 C .chi.1 372 D .chi.1
373 A .epsilon.5 374 C .epsilon.5 375 D .epsilon.5 376 A .kappa.1
377 C .kappa.1 378 D .kappa.1 379 A .theta.1 380 C .theta.1 381 D
.theta.1 382 A .kappa.2 383 C .kappa.2 384 D .kappa.2 385 A
.alpha.5 386 C .alpha.5 387 D .alpha.5 388 A .beta.10 389 C
.beta.10 390 D .beta.10 391 A .gamma.6 392 C .gamma.6 393 D
.gamma.6 394 A .nu.2 395 C .nu.2 396 D .nu.2
EXAMPLE 34
TABLE-US-00015 ##STR00105## [0227] Comp. R1 R2 397 A .theta.1 398 C
.theta.1 399 D .theta.1 400 A .alpha.4 401 A .epsilon.11 402 A
.chi.8 403 A .epsilon.9 404 A .xi.3 405 A .omega.2 406 A .alpha.6
407 A .mu.7 408 A .phi.3 409 A .tau.4 410 A .alpha.7 411 A .mu.8
412 A .alpha.1 413 A .epsilon.10 414 A .kappa.3 415 A .epsilon.12
416 A .gamma.7 417 A .gamma.8 418 A .gamma.9 419 C .alpha.4 420 C
.epsilon.11 421 C .chi.8 422 C .epsilon.9 423 C .xi.3 424 C
.omega.2 425 C .alpha.6 426 C .mu.7 427 C .phi.3 428 C .tau.4 429 C
.alpha.7 430 C .alpha.6 431 C .alpha.1 432 C .epsilon.10 433 C
.kappa.3 434 C .epsilon.12 435 C .gamma.7 436 C .gamma.8 437 C
.gamma.9 438 D .alpha.4 439 D .epsilon.11 440 D .chi.8 441 D
.epsilon.9 442 D .xi.3 443 D .omega.2 444 D .alpha.6 445 D .mu.7
446 D .phi.3 447 D .tau.4 448 D .alpha.7 449 D .mu.8 450 D .alpha.1
451 D .epsilon.10 451 D .kappa.3 453 D .epsilon.12 454 D .gamma.7
455 D .gamma.8 456 D .gamma.9
EXAMPLE 35
TABLE-US-00016 ##STR00106## [0228] Comp. R1 R2 457 D .theta.1 458 D
.beta.8 459 D .chi.3 460 D .mu.6 461 D .mu.9
EXAMPLE 36
TABLE-US-00017 ##STR00107## [0229] Comp. R1 R2 462 D .epsilon.2 463
D .sigma.1 464 D .delta.2 465 D .beta.4 466 D .phi.1
EXAMPLE 37
TABLE-US-00018 ##STR00108## [0230] Compound No. R1 R2 R3 467 E
.chi.3 .SIGMA.3 468 E .mu.6 .SIGMA.3 469 E .chi.2 .SIGMA.3 470 E
.chi.3 .psi.1 471 E .mu.6 .psi.1 472 E .sigma.3 .psi.1 473 E .chi.4
.psi.1 474 E .chi.2 .psi.1 475 C .chi.3 .psi.1 476 C .mu.6 .psi.1
477 C .sigma.3 .psi.1 478 C .chi.4 .psi.1 479 C .chi.2 .psi.1 480 A
.chi.3 .psi.1 481 A .mu.6 .psi.1 482 A .sigma.3 .psi.1 483 A .chi.4
.psi.1 484 A .chi.2 .psi.1
EXAMPLE 38
TABLE-US-00019 ##STR00109## [0231] Compound No R1 R2 R3 485 A
.chi.5 .psi.1 486 A .chi.9 .psi.1 487 A .chi.7 .psi.1 488 A .chi.10
.psi.1 489 A .chi.11 .psi.1 490 A .chi.12 .psi.1 491 A .chi.13
.psi.1 492 A .chi.14 .psi.1 493 A .chi.15 .psi.1 494 A .chi.16
.psi.1 495 A .chi.17 .psi.1 496 A .chi.18 .psi.1 497 A .chi.19
.psi.1 498 A .chi.23 .psi.1 499 A .sigma.4 .psi.1 500 A .chi.20
.psi.1 501 A .xi.4 .psi.1 502 A .beta.11 .psi.1 503 A .chi.21
.psi.1 504 A .chi.22 .psi.1 505 C .chi.5 .psi.1 506 C .chi.9 .psi.1
507 C .chi.7 .psi.1 508 C .chi.10 .psi.1 509 C .chi.11 .psi.1 510 C
.chi.12 .psi.1 511 C .chi.13 .psi.1 512 C .chi.14 .psi.1 513 C
.chi.15 .psi.1 514 C .chi.16 .psi.1 515 C .chi.17 .psi.1 516 C
.chi.18 .psi.1 517 C .chi.19 .psi.1 518 C .chi.23 .psi.1 519 C
.sigma.4 .psi.1 520 C .chi.20 .psi.1 521 C .xi.4 .psi.1 522 C
.beta.11 .psi.1 523 C .chi.21 .psi.1 524 C .chi.22 .psi.1 525 D
.chi.5 .psi.1 526 D .chi.9 .psi.1 527 D .chi.7 .psi.1 528 D .chi.10
.psi.1 529 D .chi.11 .psi.1 530 D .chi.12 .psi.1 531 D .chi.13
.psi.1 532 D .chi.14 .psi.1 533 D .chi.15 .psi.1 534 D .chi.16
.psi.1 535 D .chi.17 .psi.1 536 D .chi.18 .psi.1 537 D .chi.19
.psi.1 538 D .chi.23 .psi.1 539 D .sigma.4 .psi.1 540 D .chi.20
.psi.1 541 D .xi.4 .psi.1 542 D .beta.11 .psi.1 543 D .chi.21
.psi.1 544 D .chi.22 .psi.1 545 A .chi.5 .chi.1 546 A .chi.9
.chi.9-1 547 A .chi.7 .chi.7-1 548 A .chi.10 .chi.10-1 549 A
.chi.11 .chi.11-1 550 A .chi.12 .chi.12-1 551 A .chi.13 .chi.13-1
552 A .chi.14 .chi.14-1 553 A .chi.15 .chi.15-1 554 A .chi.16
.chi.16-1 555 A .chi.17 .chi.17-1 556 A .chi.18 .chi.18-1 557 A
.chi.19 .chi.19-1 558 A .chi.23 .chi.23-1 559 A .sigma.4 .sigma.4-1
560 A .chi.20 .chi.20-1 561 A .xi.4 .xi.4-1 562 A .beta.11 .beta.4
563 A .chi.22 .chi.22-1 564 C .chi.5 .chi.1 565 C .chi.9 .chi.9-1
566 C .chi.7 .chi.7-1 567 C .chi.10 .chi.10-1 568 C .chi.11
.chi.11-1 569 C .chi.12 .chi.12-1 570 C .chi.13 .chi.13-1 571 C
.chi.14 .chi.14-1 572 C .chi.15 .chi.15-1 573 C .chi.16 .chi.16-1
574 C .chi.17 .chi.17-1 575 C .chi.18 .chi.18-1 576 C .chi.19
.chi.19-1 577 C .chi.23 .chi.23-1 578 C .sigma.4 .sigma.4-1 579 C
.chi.20 .chi.20-1 580 C .xi.4 .xi.4-1 581 C .beta.11 .beta.4 582 C
.chi.22 .chi.22-1 583 D .chi.5 .chi.1 584 D .chi.9 .chi.9-1 585 D
.chi.7 .chi.7-1 586 D .chi.10 .chi.10-1 587 D .chi.11 .chi.11-1 588
D .chi.12 .chi.12-1 589 D .chi.13 .chi.13-1 590 D .chi.14 .chi.14-1
591 D .chi.15 .chi.15-1 592 D .chi.16 .chi.16-1 593 D .chi.17
.chi.17-1 594 D .chi.18 .chi.18-1 595 D .chi.19 .chi.19-1 596 D
.chi.23 .chi.23-1 597 D .sigma.4 .sigma.4-1 598 D .xi.4 .xi.4-1 599
D .beta.11 .beta.4 600 D .chi.22 .chi.22-1
EXAMPLE 39
TABLE-US-00020 ##STR00110## [0232] Compound No R1 R2 R3 601 A .xi.1
.alpha.1 602 A .epsilon.5 .alpha.1 603 A .epsilon.2 .alpha.1 604 A
.tau.1 .alpha.1 605 A .tau.2 .alpha.1 606 A .mu.2 .alpha.1 607 E
.tau.2 .alpha.1 608 E .mu.2 .alpha.1 609 E .mu.3 .alpha.1 610 E
.gamma.5 .alpha.1
EXAMPLE 40
TABLE-US-00021 ##STR00111## [0233] Compound No R1 R2 R3 R4 R5 611 C
.chi.4 .psi.1 .psi.1 612 F .chi.5 .psi.1 .psi.1 613 D .chi.5 .psi.1
.psi.1 614 C .chi.5 .psi.1 .psi.1 615 G .chi.5 .psi.1 .psi.1 616 H
.chi.5 .psi.1 .psi.1 617 F .chi.5 .kappa.5 .psi.1 618 D .chi.5
.kappa.5 .psi.1 619 C .chi.5 .kappa.5 .psi.1 620 G .chi.5 .kappa.5
.psi.1 621 H .chi.5 .kappa.5 .psi.1 622 F .chi.5 .psi.1 .nu.5 623 D
.chi.5 .psi.1 .nu.5 624 C .chi.5 .psi.1 .nu.5 625 G .chi.5 .psi.1
.nu.5 626 H .chi.5 .psi.1 .nu.5 627 F .chi.5 .beta.12 .beta.12 628
D .chi.5 .beta.12 .beta.12 629 C .chi.5 .beta.12 .beta.12 630 G
.chi.5 .beta.12 .beta.12 631 H .chi.5 .beta.12 .beta.12 632 F
.chi.18 .psi.1 .psi.1 633 D .chi.18 .psi.1 .psi.1 634 C .chi.18
.psi.1 .psi.1 635 G .chi.18 .psi.1 .psi.1 636 H .chi.18 .psi.1
.psi.1 637 F .chi.18 .kappa.5 .psi.1 638 D .chi.18 .kappa.5 .psi.1
639 C .chi.18 .kappa.5 .psi.1 640 G .chi.18 .kappa.5 .psi.1 641 H
.chi.18 .kappa.5 .psi.1 642 F .chi.18 .psi.1 .nu.5 643 D .chi.18
.psi.1 .nu.5 644 C .chi.18 .psi.1 .nu.5 645 G .chi.18 .psi.1 .nu.5
646 H .chi.18 .psi.1 .nu.5 647 F .chi.18 .beta.12 .beta.12 648 D
.chi.18 .beta.12 .beta.12 649 C .chi.18 .beta.12 .beta.12 650 G
.chi.18 .beta.12 .beta.12 651 H .chi.18 .beta.12 .beta.12 652 F
.chi.4 .psi.1 .psi.1 653 D .chi.4 .psi.1 .psi.1 654 G .chi.4 .psi.1
.psi.1 655 H .chi.4 .psi.1 .psi.1 656 F .chi.4 .kappa.5 .psi.1 657
D .chi.4 .kappa.5 .psi.1 658 C .chi.4 .kappa.5 .psi.1 659 G .chi.4
.kappa.5 .psi.1 660 H .chi.4 .kappa.5 .psi.1 661 F .chi.4 .psi.1
.nu.5 662 D .chi.4 .psi.1 .nu.5 663 C .chi.4 .psi.1 .nu.5 664 G
.chi.4 .psi.1 .nu.5 665 H .chi.4 .psi.1 .nu.5 666 F .chi.4 .beta.12
.beta.12 667 D .chi.4 .beta.12 .beta.12 668 C .chi.4 .beta.12
.beta.12 669 G .chi.4 .beta.12 .beta.12 670 H .chi.4 .beta.12
.beta.12 671 F .chi.5 .chi.1 .psi.1 .psi.1 672 D .chi.5 .chi.1
.psi.1 .psi.1 673 C .chi.5 .chi.1 .psi.1 .psi.1 674 G .chi.5 .chi.1
.psi.1 .psi.1 675 H .chi.5 .chi.1 .psi.1 .psi.1 676 F .chi.5 .chi.1
.kappa.5 .psi.1 677 D .chi.5 .chi.1 .kappa.5 .psi.1 678 C .chi.5
.chi.1 .kappa.5 .psi.1 679 G .chi.5 .chi.1 .kappa.5 .psi.1 680 H
.chi.5 .chi.1 .kappa.5 .psi.1 681 F .chi.5 .chi.1 .psi.1 .nu.5 682
D .chi.5 .chi.1 .psi.1 .nu.5 683 C .chi.5 .chi.1 .psi.1 .nu.5 684 G
.chi.5 .chi.1 .psi.1 .nu.5 685 H .chi.5 .chi.1 .psi.1 .nu.5 686 D
.chi.5 .chi.1 .beta.12 .beta.12 687 C .chi.5 .chi.1 .beta.12
.beta.12 688 G .chi.5 .chi.1 .beta.12 .beta.12 689 H .chi.5 .chi.1
.beta.12 .beta.12 690 F .chi.18 .chi.18-1 .psi.1 .psi.1 691 C
.chi.18 .chi.18-1 .psi.1 .psi.1 692 G .chi.18 .chi.18-1 .psi.1
.psi.1 693 H .chi.18 .chi.18-1 .psi.1 .psi.1 694 H .chi.18
.chi.18-1 .kappa.5 .psi.1 695 F .chi.18 .chi.18-1 .psi.1 .nu.5 696
C .chi.18 .chi.18-1 .psi.1 .nu.5 697 D .chi.18 .chi.18-1 .psi.1
.nu.5 698 G .chi.18 .chi.18-1 .psi.1 .nu.5 699 H .chi.18 .chi.18-1
.psi.1 .nu.5 700 F .chi.18 .chi.18-1 .beta.12 .beta.12 701 D
.chi.18 .chi.18-1 .beta.12 .beta.12 702 C .chi.18 .chi.18-1
.beta.12 .beta.12 703 G .chi.18 .chi.18-1 .beta.12 .beta.12 704 H
.chi.18 .chi.18-1 .beta.12 .beta.12 705 F .chi.4 .chi.24 .psi.1
.psi.1 706 C .chi.4 .chi.24 .psi.1 .psi.1 707 G .chi.4 .chi.24
.psi.1 .psi.1 708 H .chi.4 .chi.24 .psi.1 .psi.1 709 F .chi.4
.chi.24 .kappa.5 .psi.1 710 D .chi.4 .chi.24 .kappa.5 .psi.1 711 C
.chi.4 .chi.24 .kappa.5 .psi.1 712 H .chi.4 .chi.24 .kappa.5 .psi.1
713 D .chi.4 .chi.24 .psi.1 .nu.5 714 F .chi.4 .chi.24 .beta.12
.beta.12
EXAMPLE 41
TABLE-US-00022 ##STR00112## [0234] Compound No. R1 R2 R3 715 A
.chi.5 .alpha.1 716 C .chi.5 .alpha.1 717 A .chi.3 .alpha.1 718 C
.chi.3 .alpha.1 719 A .sigma.3 .alpha.1 720 C .sigma.3 .alpha.1 721
A .chi.5 .nu.5 722 C .chi.5 .nu.5 723 C .chi.5 .nu.5 724 A .chi.3
.nu.5 725 C .chi.3 .nu.5 726 C .chi.3 .nu.5 727 A .sigma.3 .nu.5
728 C .sigma.3 .nu.5 729 C .sigma.3 .nu.5
EXAMPLE 42
TABLE-US-00023 ##STR00113## [0235] Compound No R1 R2 R3 730 A
.beta.2 .alpha.1 731 A .epsilon.5 .alpha.1 732 A .beta.3 .alpha.1
733 A .chi.19 .alpha.1 734 A .chi.1 .alpha.1 735 A .gamma.10
.alpha.1 736 A .xi.5 .alpha.1 737 A .sigma.1 .alpha.1 738 A
.chi.4-1 .alpha.1 739 A .mu.10 .alpha.1 740 A .phi.2 .alpha.1 741 A
.alpha.4 .alpha.1 742 A .alpha.8 .alpha.1 743 A .beta.2 .beta.2 744
A .epsilon.5 .beta.2 745 A .beta.3 .beta.2 746 A .chi.19 .beta.2
747 A .chi.1 .beta.2 748 A .gamma.10 .beta.2 749 A .xi.5 .beta.2
750 A .sigma.1 .beta.2 751 A .chi.4-1 .beta.2 752 A .mu.10 .beta.2
753 A .phi.2 .beta.2 754 A .alpha.4 .beta.2 755 A .alpha.8 .beta.2
756 A .beta.2 .epsilon.5 757 A .epsilon.5 .epsilon.5 758 A .beta.3
.epsilon.5 759 A .chi.19 .epsilon.5 760 A .chi.1 .epsilon.5 761 A
.gamma.10 .epsilon.5 762 A .xi.5 .epsilon.5 763 A .sigma.1
.epsilon.5 764 A .chi.4-1 .epsilon.5 765 A .mu.10 .epsilon.5 766 A
.phi.2 .epsilon.5 767 A .alpha.4 .epsilon.5 768 A .alpha.8
.epsilon.5 769 A .beta.2 .xi.1 770 A .epsilon.5 .xi.1 771 A .beta.3
.xi.1 772 A .chi.1 .xi.1 773 A .gamma.10 .xi.1 774 A .sigma.1 .xi.1
775 A .chi.4-1 .xi.1 776 A .mu.10 .xi.1 777 A .phi.2 .xi.1 778 A
.alpha.4 .xi.1 779 A .alpha.8 .xi.1 780 A .beta.2 .psi.1 781 A
.beta.2 .xi.5 782 A .epsilon.5 .psi.1 783 A .epsilon.5 .xi.5 784 A
.beta.3 .psi.1 785 A .beta.3 .xi.5 786 A .chi.1 .psi.1 787 A .chi.1
.xi.5 788 A .gamma.10 .psi.1 789 A .gamma.10 .xi.5 790 A .xi.5
.psi.1 791 A .xi.5 .xi.5 792 A .sigma.1 .psi.1 793 A .sigma.1 .xi.5
794 A .chi.4-1 .psi.1 795 A .mu.10 .psi.1 796 A .mu.10 .xi.5 797 A
.phi.2 .psi.1 798 A .phi.2 .xi.5 799 A .alpha.8 .xi.5 800 A
.alpha.8 .xi.5 801 A .beta.2 .omega.1 802 A .epsilon.5 .omega.1 803
A .beta.3 .omega.1 804 A .chi.19 .omega.1 805 A .chi.1 .omega.1 806
A .chi.19 .psi.1 807 A .chi.19 .xi.5 808 A .phi.2 .omega.1 809 A
.mu.10 .gamma.1 810 A .phi.2 .gamma.1 811 A .alpha.4 .gamma.1 812 A
.alpha.8 .gamma.1 813 A .beta.2 .kappa.2 814 A .epsilon.5 .kappa.2
815 A .beta.3 .kappa.2 816 A .chi.19 .kappa.2 817 A .chi.1 .kappa.2
818 A .gamma.10 .kappa.2 819 A .chi.5 .kappa.2 820 A .sigma.1
.kappa.2 821 A .chi.4-1 .kappa.2 822 A .mu.10 .kappa.2 823 A .phi.2
.kappa.2 824 A .alpha.4 .kappa.2 825 A .alpha.8 .kappa.2 826 A
.beta.2 .tau.2 827 A .epsilon.5 .tau.2 828 A .beta.3 .tau.2 829 A
.chi.19 .tau.2 830 A .chi.1 .tau.2 831 A .gamma.10 .tau.2 832 A
.chi.5 .tau.2 833 A .sigma.1 .tau.2 834 A .chi.4-1 .tau.2 835 A
.mu.10 .tau.2 836 A .phi.2 .tau.2 837 A .alpha.4 .tau.2 838 A
.alpha.8 .tau.2 839 A .beta.2 .tau.2 840 A .epsilon.5 .mu.2 841 A
.beta.3 .mu.2 842 A .chi.19 .mu.2 843 A .chi.1 .mu.2 844 A
.gamma.10 .mu.2 845 A .chi.5 .mu.2 846 A .mu.2 .mu.2 847 A .chi.4-1
.mu.2 848 A .mu.10 .mu.2 849 A .phi.2 .mu.2 850 A .alpha.4 .mu.2
851 A .alpha.8 .mu.2 852 A .beta.2 .chi.1 853 A .epsilon.5 .chi.1
854 A .beta.3 .chi.1 855 A .chi.19 .chi.1 856 A .chi.1 .chi.1 857 A
.gamma.10 .chi.1 858 A .chi.5 .chi.1 859 A .sigma.1 .chi.1 860 A
.xi.4-1 .chi.1 861 A .phi.2 .chi.1 862 A .alpha.4 .chi.1 863 A
.alpha.8 .chi.1 864 A .beta.2 .SIGMA.4 865 A .epsilon.5 .SIGMA.4
866 A .beta.3 .SIGMA.4 867 A .chi.19 .SIGMA.4 868 A .chi.1 .SIGMA.4
869 A .gamma.10 .SIGMA.4 870 A .chi.5 .SIGMA.4 871 A .sigma.1
.SIGMA.4 872 A .chi.4-1 .SIGMA.4 873 A .mu.10 .SIGMA.4 874 A .phi.2
.SIGMA.4 875 A .alpha.4 .SIGMA.4 876 A .alpha.8 .SIGMA.4 877 A
.alpha.1 .nu.1 878 A .alpha.1 .nu.2 879 A .alpha.1 .nu.9 880 A
.nu.4 .alpha.1 881 A .nu.4 .gamma.2 882 A .nu.4 .tau.2 883 A .nu.4
.tau.1 884 A .chi.1 .nu.4 885 A .mu.7-1 .alpha.1 886 A .mu.7-1
.gamma.2 887 A .mu.7-1 .tau.2 888 A .mu.7-1 .tau.1 889 A .mu.7-1
.chi.1 890 A .gamma.10 .epsilon.1 891 A .chi.5 .omega.1 892 A
.sigma.1 .omega.1 893 A .chi.4-1 .omega.1 894 A .mu.10 .omega.1 895
A .alpha.4 .omega.1 896 A .alpha.8 .omega.1 897 A .beta.2 .gamma.1
898 A .epsilon.5 .gamma.1 899 A .beta.3 .gamma.1 900 A .chi.19
.gamma.1 901 A .chi.1 .gamma.1 902 A .gamma.10 .gamma.1 903 A .xi.5
.gamma.1 904 A .sigma.1 .gamma.1 905 A .chi.4-1 .gamma.1 906 A
.mu.11 .chi.1 907 A .mu.11 .tau.2 908 A .nu.4 .mu.3 909 A .alpha.1
.sigma.1 910 A .sigma.1 .beta.2 911 A .sigma.1 .epsilon.5
EXAMPLE 43
TABLE-US-00024 ##STR00114## [0236] Compound No R1 R2 R3 R4 912 A
.chi.4 .psi.1 .psi.1 913 A .chi.5 .psi.1 .psi.1 914 A .chi.18
.psi.1 .psi.1 915 A .chi.5 .psi.1 .nu.5 916 A .chi.18 .psi.1 .nu.5
917 A .chi.5 .kappa.5 .psi.1 918 A .chi.4 .kappa.5 .psi.1 919 A
.chi.18 .kappa.5 .psi.1 920 A .chi.5 .beta.12 .beta.12 921 A .chi.4
.beta.12 .beta.12 922 A .chi.18 .beta.12 .beta.12
EXAMPLE 44
TABLE-US-00025 ##STR00115## [0237] Compound No R1 R2 R3 923 A
.alpha.1 .alpha.4 924 A .alpha.1 .beta.6 925 A .alpha.1 .epsilon.9
926 A .alpha.1 .kappa.6 927 A .alpha.1 .sigma.3 928 A .alpha.1
.chi.8 929 A .psi.1 .alpha.4 930 A .psi.1 .beta.6 931 A .psi.1
.epsilon.9 932 A .psi.1 .kappa.6 933 A .psi.1 .sigma.3 934 A .psi.1
.chi.8 935 A .mu.7-1 .alpha.4 936 A .mu.7-1 .beta.6 937 A .mu.7-1
.epsilon.9 938 A .mu.7-1 .kappa.6 939 A .mu.7-1 .sigma.3 940 A
.mu.7-1 .chi.8 941 A .mu.13 .alpha.4 942 A .mu.13 .beta.6 943 A
.mu.13 .epsilon.9 944 A .mu.13 .kappa.6 945 A .mu.13 .sigma.3 946 A
.mu.13 .chi.8 947 A .alpha.1 .alpha.4 948 A .alpha.1 .beta.6 949 A
.mu.7-1 .alpha.4 950 A .mu.7-1 .beta.6 951 A .mu.7-1 .sigma.3 952 A
.mu.13 .sigma.3 953 A .mu.13 .chi.8
EXAMPLE 45
TABLE-US-00026 ##STR00116## [0238] Compound No R1 R2 R3 954 A
.beta.4 .alpha.1 955 A .beta.2 .alpha.1 956 A .epsilon.3 .alpha.1
957 A .gamma.2 .alpha.1 958 A .gamma.1 .alpha.1 959 A .beta.3
.alpha.1 960 A .beta.4 .alpha.1 961 A .beta.2 .alpha.1 962 A
.epsilon.3 .alpha.1 963 A .gamma.2 .alpha.1 964 A .gamma.1 .alpha.1
965 A .beta.3 .alpha.1
EXAMPLE 46
TABLE-US-00027 ##STR00117## [0239] Compound No R1 R2 R3 R4 966 C
.alpha.1 .psi.1 .psi.1 967 G .alpha.1 .psi.1 .psi.1 968 H .alpha.1
.psi.1 .psi.1 969 C .alpha.1 .kappa.5 .psi.1 970 G .alpha.1
.kappa.5 .psi.1 971 H .alpha.1 .kappa.5 .psi.1 972 C .alpha.1
.psi.1 .nu.5 973 G .alpha.1 .psi.1 .nu.5 974 H .alpha.1 .psi.1
.nu.5 975 C .alpha.1 .beta.12 .beta.12 976 G .alpha.1 .beta.12
.beta.12 977 h .alpha.1 .beta.12 .beta.12
EXAMPLE 47
TABLE-US-00028 ##STR00118## [0240] Compound No. R1 R2 R3 978 A
.sigma.2 .sigma.2-1 979 A .xi.2 .xi.2-1 980 A .beta.6 .beta.2 981 A
.theta.1 .theta.3 982 A .epsilon.8 .epsilon.1 983 A .beta.8 .beta.3
984 A .pi.5 .pi.1 985 A .tau.3 .tau.1 986 A .alpha.3 .alpha.3-1 987
A .tau.4 .tau.2 988 A .sigma.3 .sigma.1 989 C .chi.2 .chi.2-1 990 C
.chi.3 .xi.3-1 991 C .chi.4 .chi.4-1 992 C .nu.8 .nu.1 993 C .mu.5
.mu.5-1 994 C .tau.3 .tau.1 995 C .tau.4 .tau.2 996 C .mu.6 .mu.6-1
997 D .sigma.2 .sigma.2-1 998 D .xi.2 .xi.2-1 999 D .beta.6 .beta.2
1000 D .phi.1 .phi.1-1 1001 D .chi.4 .chi.4-1 (.chi.24) 1002 D
.nu.8 .nu.1 1003 D .tau.4 .tau.2 1004 D .sigma.3 .sigma.1 1005 D
.beta.9 .beta.9-1 1006 D .mu.6 .mu.6-1 1007 A .chi.2 .chi.2-1
EXAMPLE 48
TABLE-US-00029 ##STR00119## [0241] Compound No. R1 R2 R3 1008 A
.alpha.4 .alpha.1 1009 A .epsilon.11 .epsilon.3 1010 A .chi.8
.chi.8-1 1011 A .epsilon.9 .epsilon.5 1012 A .epsilon.2 .epsilon.1
1013 A .alpha.6 .alpha.6-1 1014 A .phi.3 .phi.2 1015 A .tau.4
.tau.5 1016 A .alpha.7 .alpha.7-1 1017 A .alpha.1 .alpha.5 1018 A
.epsilon.10 .epsilon.2 1019 A .kappa.3 .kappa.7 1020 A .epsilon.12
.epsilon.7 1021 A .gamma.7 .gamma.4 1022 A .gamma.8 .gamma.8-1 1023
A .gamma.9 .gamma.5 1024 C .alpha.4 .alpha.1 1025 C .theta.1
.theta.3 1026 C .epsilon.11 .epsilon.3 1027 C .chi.8 .chi.8-1 1028
C .epsilon.9 .epsilon.5 1029 C .epsilon.3 .epsilon.1 1030 C
.alpha.6 .alpha.6-1 1031 C .phi.3 .phi.2 1032 C .tau.4 .tau.5 1033
C .alpha.7 .alpha.7-1 1034 C .alpha.1 .alpha.5 1035 C .epsilon.10
.epsilon.2 1036 C .kappa.3 .kappa.7 1037 C .epsilon.12 .epsilon.7
1038 C .gamma.7 .gamma.4 1039 C .gamma.8 .gamma.8-1 1040 C .gamma.9
.gamma.5 1041 D .alpha.4 .alpha.1 1042 D .theta.1 .theta.3 1043 D
.epsilon.11 .epsilon.3 1045 D .chi.8 .chi.8-1 1046 D .epsilon.9
.epsilon.5 1047 D .epsilon.2 .epsilon.1 1048 D .alpha.6 .alpha.6-1
1049 D .phi.3 .phi.2 1050 D .alpha.7 .alpha.7-1 1051 D .epsilon.10
.epsilon.2 1052 D .kappa.3 .kappa.7 1053 D .epsilon.12 .epsilon.7
1054 D .gamma.7 .gamma.4 1055 D .gamma.8 .gamma.8-1
EXAMPLE 49
Selected Activity Data Tested at 25 Micromolar Except ! Tested at
2.5 Micromolar
TABLE-US-00030 [0242] compound number EGF-R c-Kit VEGF ABL MET
PDGFalpha CDK2 Tie2 PKC P38 100 69 52 58 109 88 106 70 42 80 146 94
53 101 115 78 127 270 71 142 212 23 12 10 41 46 38 25 1 26 223 22
109 11 24 31 17 40 0 10 246 15 6 8 30 27 28 26 -1 13 279 66 17 31 6
72 85 20 12 80 345 58 40 54 74 87 82 67 41 65 456 96 92 96 107 103
113 28 91 104 466 84 55 72 110 102 104 114 88 87 486! 24 45 96 100
488! 34 136 82 100 508! 12 17 16 100 528! 12 44 26 101 604 27 13 18
49 46 46 30 3 50 100 605 20 18 14 55 54 56 26 5 27 100 658! 20 55 5
99 659! 17 63 8 94 668! 16 1 669! 11 34 1 97 670! 9 23 1 718! 7 8 1
725! 6 10 912 88 38 44 96 88 96 119 72 96 70 Blank = not
determined.
[0243] The following lists examples of compound numbers that
demonstrate activity
[0244] EGF-R inhibitors at 25 micromolar: 470, 471, 472, 478, 480,
604, 605, 611, 100, 198, 205, 207, 209, 212, 213, 214, 215, 216,
218, 211, 220, 221, 222, 223, 224, 225, 227, 233, 235, 238, 240,
241, 246, 248, 254, 273, 279, 291, 334, 345, 350, 386, 391, 392,
393:
[0245] c-Kit inhibitors at 25 micromolar: 470, 471, 472, 473, 474,
480, 482, 483, 484, 604, 605, 611, 912, 486, 488, 501, 504, 508,
528, 606, 607, 608, 609, 610, 654, 657, 658, 659, 660, 663, 664,
665, 666, 667, 668, 669, 670, 99, 100, 103, 104, 108, 109, 110,
122, 125, 127, 130, 131, 132, 133, 135, 136, 137, 138, 139, 140,
143, 144, 145, 146, 148, 154, 155, 163, 168, 169, 170, 173, 174,
175, 177, 178, 180, 181, 183, 184, 186, 192, 193, 198, 204, 205,
207, 209, 212, 213, 214, 217, 218, 211, 220, 221, 222, 225, 227,
233, 235, 238, 240, 241, 246, 248, 254, 228, 242, 244, 245, 247,
250, 252, 253, 260, 261, 262, 271, 264, 273, 279, 282, 286, 289,
291, 299, 309, 321, 322, 332, 333, 334, 345, 346, 362, 370, 377,
378, 379, 386, 398, 403, 404, 408, 427, 458, 459, 460, 462, 463,
464, 465, 466:
[0246] VEGF-R2 inhibitors at 25 micromolar: 472, 478, 480, 482,
483, 484, 604, 605, 611, 912, 486, 505, 508, 528, 604, 605, 606,
608, 658, 659, 660, 667, 668, 669, 670, 100, 198, 205, 207, 209,
211, 212, 214, 215, 216, 218, 220, 221, 222, 223, 224, 225, 227,
233, 235, 238, 244, 246, 252, 254, 256, 271, 273, 279, 291, 345,
370, 371, 379, 403, 466:
[0247] ABL inhibitors at 25 micromolar 470, 478, 480, 604, 605,
611, 107, 127, 135, 152, 156, 157, 158, 159, 191, 207, 212, 214,
215, 220, 221, 223, 224, 225, 233, 246, 273, 279, 291, 299, 330,
334, 345, 397:
[0248] MET inhibitors at 25 micromolar: 470, 480, 604, 605, 207,
212, 214, 217, 220, 221, 223, 224, 225, 233, 238, 246, 279,
291:
[0249] PDGF-Ralpha inhibitors at 25 micromolar: 470, 604, 605, 207,
212, 214, 215, 220, 221, 223, 224, 225, 233, 246, 202, 271, 321,
334, 370:
[0250] CDK2 inhibitors at 25 micromolar: 470, 472, 478, 604, 605,
611, 32, 100, 205, 207, 209, 212, 213, 214, 215, 216, 218, 219,
220, 221, 222, 223, 224, 225, 233, 246, 273, 279, 291, 334, 345,
456:
[0251] Tie2 inhibitors at 25 micromolar: 470, 471, 472, 474, 478,
480, 604, 605, 611, 912, 508, 528, 534, 535, 604, 605, 606, 607,
608, 609, 610, 654, 657, 658, 659, 660, 667, 668, 669, 670, 71, 91,
92, 99, 100, 101, 103, 104, 106, 107, 108, 109, 113, 114, 127, 131,
135, 136, 138, 139, 143, 144, 145, 146, 151, 152, 153, 154, 155,
160, 168, 177, 178, 183, 192, 198, 205, 207, 209, 211, 212, 217,
214, 215, 216, 218, 220, 221, 222, 223, 224, 225, 227, 231, 233,
235, 238, 240, 241, 244, 246, 248, 250, 252, 254, 256, 271, 273,
279, 291, 333, 334, 345, 376, 379, 446, 457, 459:
[0252] PK-C inhibitors at 25 micromolar: 470, 471, 472, 474, 478,
480, 604, 605, 611, 2, 205, 207, 209, 212, 213, 214, 215, 216, 218,
219, 220, 221, 222, 223, 224, 225, 233, 246, 299, 321, 333, 334,
345, 379:
[0253] FGF-R1 inhibitors at 25 micromolar: 604, 605, 611, 100, 104,
198, 205, 207, 211, 212, 214, 215, 216, 217, 218, 220, 221, 222,
223, 224, 225, 227, 233, 238, 246, 248, 254, 273, 279, 291,
345:
TABLE-US-00031 Tables of Substituents: ##STR00120## ##STR00121##
##STR00122## ##STR00123## ##STR00124## ##STR00125## ##STR00126##
##STR00127## ##STR00128## ##STR00129## ##STR00130## ##STR00131##
##STR00132## ##STR00133## ##STR00134## ##STR00135## ##STR00136##
##STR00137## ##STR00138## ##STR00139## ##STR00140## ##STR00141##
##STR00142## ##STR00143## ##STR00144## ##STR00145## ##STR00146##
##STR00147## ##STR00148## ##STR00149## ##STR00150## ##STR00151##
##STR00152## ##STR00153## ##STR00154## ##STR00155## ##STR00156##
##STR00157## ##STR00158## ##STR00159## ##STR00160## ##STR00161##
##STR00162## ##STR00163## ##STR00164## ##STR00165## ##STR00166##
##STR00167## ##STR00168## ##STR00169## ##STR00170## ##STR00171##
##STR00172## ##STR00173## ##STR00174## ##STR00175## ##STR00176##
##STR00177## ##STR00178## ##STR00179## ##STR00180## ##STR00181##
##STR00182## ##STR00183## ##STR00184## ##STR00185## ##STR00186##
##STR00187## ##STR00188## ##STR00189## ##STR00190## ##STR00191##
##STR00192## ##STR00193## ##STR00194## ##STR00195## ##STR00196##
##STR00197## ##STR00198## ##STR00199## ##STR00200## ##STR00201##
##STR00202## ##STR00203## ##STR00204## ##STR00205## ##STR00206##
##STR00207## ##STR00208## ##STR00209## ##STR00210## ##STR00211##
##STR00212## ##STR00213## ##STR00214## ##STR00215## ##STR00216##
##STR00217## ##STR00218## ##STR00219## ##STR00220## ##STR00221##
##STR00222## ##STR00223## ##STR00224## ##STR00225## ##STR00226##
##STR00227## ##STR00228## ##STR00229## ##STR00230## ##STR00231##
##STR00232## ##STR00233## ##STR00234## ##STR00235## ##STR00236##
##STR00237## ##STR00238## ##STR00239## ##STR00240## ##STR00241##
##STR00242## ##STR00243## ##STR00244## ##STR00245## ##STR00246##
##STR00247## ##STR00248## ##STR00249## ##STR00250## ##STR00251##
##STR00252## ##STR00253## ##STR00254## ##STR00255## ##STR00256##
##STR00257## ##STR00258## ##STR00259## ##STR00260## ##STR00261##
##STR00262## ##STR00263## ##STR00264## ##STR00265## ##STR00266##
##STR00267## ##STR00268## ##STR00269## ##STR00270## ##STR00271##
##STR00272## ##STR00273## ##STR00274## ##STR00275## ##STR00276##
##STR00277## ##STR00278## ##STR00279## ##STR00280##
##STR00281##
[0254] Throughout the specification and the claims (if present),
unless the context requires otherwise, the term "comprise", or
variations such as "comprises" or "comprising", will be understood
to apply the inclusion of the stated integer or group of integers
but not the exclusion of any other integer or group of
integers.
[0255] It should be appreciated that various other changes and
modifications can be made to any embodiment described without
departing from the spirit and scope of the invention
* * * * *